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Background and purpose: N-methyl-D-aspartate receptor (NMDAR) 
antagonism has been proposed to be a therapeutic approach to reduce neuronal 
death in the penumbra region during acute ischemic stroke. Early non-selective 
NMDAR antagonists, however, have repeatedly failed in clinical trials due to 
inefficacy and adverse effects. As such, subunit-selective antagonists have been 
proposed to be a safer alternative, with studies focusing on the GluN2B (also 
known as NR2B) subunit due to its role in excitotoxic cell death. Two classes of 
5-substituted benzimidazole derivatives, the benzylpiperidine benzimidazoles and 
the phenoxyphenyl benzimidazoles, have been previously reported to be high 
affinity GluN2B subunit-selective antagonists. Previous work by our laboratory to 
characterize the inhibitory profile of benzylpiperidine benzimidazole N-{2-[(4-
benzylpiperidin-1-yl)methyl]benzimidazol-5-yl}methanesulphonamide (XK1) 
and phenoxyphenyl benzimidazole N-[2-(4-phenoxybenzyl)benzimidazol-5-
yl]methanesulfonamide (XK2) demonstrated that both compounds showed good 
efficacy in an in vitro neuronal excitotoxicty model. The demonstration of 
neuroprotective properties in vitro by these two compounds suggested a possible 
role of 5-substituted benzimidazole derivatives as stroke neuroprotectants. 
Nevertheless, we are unaware of any studies that have evaluated their effects in 
stroke.  Hence, in this study, we attempted to characterize the inhibitory profile of 
another benzylpiperidine benzimidazole 2-{[4-(2-fluorobenzyl)piperidin-1-
ix 
 
yl]methyl}benzimidazole-5-ol (YY1), as well as evaluate the efficacy of YY1 and 
XK2 as stroke neuroprotectants in vivo.   
 
Experimental approach: The neuroprotective properties of YY1 in vitro were 
evaluated using rat primary cerebrocortical neurons while its inhibition of 
GluN1/GluN2B receptors was characterized using two–electrode voltage clamp 
on Xenopus oocytes. The neuroprotective effects of YY1 and XK2 in vivo were 
evaluated using the permanent middle cerebral artery occlusion (pMCAO) stroke 
model. YY1 and XK2 were administered intraperitoneally one hour prior to 
pMCAO and the resultant infarct volume and neurological deficits evaluated 24 
hours after occlusion.  
 
Results: Similar to XK1 and XK2, YY1 dose-dependently protected 
cerebrocortical neurons against NMDA-induced neuronal death with an IC50 
value of 15.3 nM. YY1 failed to inhibit current measured from oocytes 
heterologously expressing GluN1 and amino terminal domain (ATD)-truncated 
GluN2B subunits, suggesting a vital role of the GluN2B subunit in its inhibition. 
YY1 was also stably docked onto the GluN2B ATD crystal structure and showed 
a greater inhibition of GluN1/GluN2B receptors at an acidic pH. In the rat stroke 
model, YY1 and XK2 reduced infarct volume in a dose-dependent manner, with a 
significant reduction of 40% observed at a dosage of 3 mg/kg for both 




Conclusions: These results demonstrated that 5-substituted benzimidazole 
derivatives exemplified by YY1 and XK2 are neuroprotective in vitro and in vivo. 
The inhibition of GluN1/GluN2B receptors for neuroprotection by these 
compounds was also shown to be mediated through the GluN2B ATD. In 
addition, the pH-dependent inhibition of GluN1/GluN2B receptors by both 
compounds may suggest a possible role in prophylactic neuroprotection, with the 
advantage of selectively inhibiting GluN1/GluN2B receptors in ischemic tissues 
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Structure of Thesis 
 
The thesis is divided into the following chapters: 
 
Chapter 1: Introduction 
This chapter provides an overview of stroke and the NMDARs, covering areas 
such as pathophysiology, treatment strategies and experimental models for the 
section on stroke, and structure and function for the section on NMDARs. 
Promising NMDAR antagonists that had progressed to clinical trials for acute 
ischemic stroke and the potential of 5-substituted benzimidazole derivatives as 
stroke neuroprotectants will also be discussed.   
 
Chapter 2: In vitro characterization of benzylpiperidine benzimidazole YY1 
This chapter evaluates the in vitro neuroprotective effects of YY1 in rat 
cerebrocortical neurons, as well as characterizes its inhibition of GluN1/GluN2B 
receptors, determining the NMDAR subunit domain that is responsible for 
conferring its sensitivity. 
 
Chapter 3: Docking and molecular dynamics simulations of YY1 in the 
GluN2B ATD crystal structure   
This chapter discusses the docking of YY1 into the central binding cleft of the 
GluN2B ATD crystal structure, examines its interactions with cleft residues, as 
xviii 
 
well as identifies new cleft residues that may potentially influence its inhibition of 
GluN1/GluN2B receptors. 
 
Chapter 4: Mechanism of inhibition by YY1 
This chapter examines the probable mechanism of inhibition by YY1.  
 
Chapter 5: In vivo neuroprotective potential of YY1 and XK2 in a rat model 
of permanent cerebral ischemia 
This chapter evaluates the in vivo neuroprotective potentials of YY1 and XK2. 
 
Chapter 6: Conclusion and future directions 
This chapter summarizes the findings of the study and the implications derived 
from them. The limitations of the study will also be discussed and the thesis will 





























1.1 Stroke  
Stroke is often dubbed as the brain equivalent of a heart attack (WHO, 2011) . 
The brain, which is critically dependent on aerobic metabolism of glucose for 
energy, requires a steady supply of oxygen and glucose from the blood. Stroke 
thus occurs when an obstruction in blood flow to the brain by a blood clot or the 
narrowing or bursting of the blood vessels limits the supply of oxygen and 
glucose, causing extensive damage to brain tissues.  
 
1.1.1 Epidemiology of Stroke 
Stroke is a major health concern, ranking as the third most common cause 
of death behind heart disease and cancer (Lloyd-Jones et al., 2010). With one-
third of stroke survivors left permanently disabled, stroke is also a leading cause 
of long-term disability and a heavy burden for the family and community (WHO, 
2011). In Singapore alone, stroke is the fourth leading cause of death, constituting 
approximately 8% of total deaths in 2009 (MOH, 2011).  
 
Epidemiological studies in recent years have reported a decline in the 
incidence of stroke in many developed countries, largely due to improved 
management of stroke risk factors such as hypertension and smoking (WHO, 
2011). Stroke, nevertheless, remains as a health issue of high importance, as the 
absolute number of stroke continues to increase, owing to a progressively ageing 




1.1.2 Classification of Stroke 
Stroke can be broadly classified into ischemic stroke and hemorrhagic 
stroke, the distinction of which could be deduced by computed tomography (CT) 
or magnetic resonance imaging (MRI). Ischemic stroke constitutes 80% of all 
strokes while hemorrhagic stroke constitutes the remaining 20% (Donnan et al., 
2008).  
 
Ischemic stroke can be caused by either a thrombosis (blockage of a blood 
vessel by a local thrombus), an embolism (blockage of a blood vessel by an 
embolus from other parts of the body), a systemic hypoperfusion (reduction of 
blood flow to all parts of the body) or a venous thrombosis (blockage by a blood 
clot that forms in a vein), all of which result in a blockage of blood supply to the 
brain (Deb et al., 2010). Hemorrhagic stroke, on the other hand, is caused by the 
rupture of a weakened blood vessel, which could take the form of an aneurysm or 
an arteriovenous malformation (Donnan et al., 2008). Ischemic stroke will be the 
focus of this study. 
 
1.1.3 Pathophysiology of Ischemic Stroke 
The brain, being completely dependent on aerobic metabolism of glucose 
for energy, is extremely vulnerable to the effects of ischemia. Occlusion of blood 
flow to the brain for a short five to ten minutes could thus result in irreversible 




In the event of an ischemic stroke, regions of brain tissue undergo 
different degrees of injury due to the presence of collateral circulation (Deb et al., 
2010). In particular, brain tissue in the immediate vicinity (core) of the stroke 
insult undergoes necrosis due to the complete occlusion of blood flow while brain 
tissues at the periphery of the core (penumbra) may only be partially injured due 
to partial blood flow supplied by collateral arteries. Given time and without 
treatment, neurons within the ischemic penumbra would die and the area of 
infarct widens, owing to various mechanisms constituting the ischemic cascade 
(Figure 1-1). These mechanisms include excitotoxicity, inflammation, cerebral 
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Figure 1-1 Overview of the pathophysiological mechanisms with the onset of 
ischemia. The ischemic cascade begins with the depletion of ATP due to the 
compromised blood flow to the brain. Energy dependent processes thus cease to 
function, resulting in the depolarization of neurons when membrane potential is 
loss. Excessive release of glutamate overactivates glutamate receptors, leading to 
the influx of Na2+, Cl- and Ca2+ ions. Na2+ pulls water into the intracellular space, 
causing edema. Ca2+, on the other hand, causes the disordered activation of 
enzymes such as proteases, lipases, nucleases, as well as mechanisms generating 






1.1.3.1 Energy Failure and Excitotoxicity 
 In the event of an ischemic stroke, the disruption of blood flow to the 
brain limits the supply of oxygen and glucose necessary for the formation of high 
energy phosphate compounds such as adenosine triphosphate (ATP). With the 
depletion of ATP in the brain, energy processes cease to function, triggering a 
series of inter-related events, eventually leading to cellular injury and neuronal 
death (Rang et al., 2007). In particular, excitotoxicity has been widely recognized 
as one of the main mechanisms contributing to neuronal death in brain ischemia.  
  
With the depletion of energy in the brain, ionic gradients across 
membranes could not be effectively maintained, resulting in the depolarization of 
neurons and gial cells. This results in the influx of ions such as sodium, chloride 
and calcium, as well as the release of excitatory neurotransmitters such as 
glutamate into the extracellular space. Glutamate is a vital neurotransmitter in the 
brain, playing important roles in the regulation of synaptic transmission. It is, 
however, toxic in excess, as would take place in the event of an ischemic stroke 
(Olney, 1969; Olney et al., 1969). During normal situations, the level of 
glutamate in the extracellular space is regulated by the presynaptic re-uptake 
transporters. These re-uptake processes, however, are impeded during ischemia, 
with the depletion of ATP. Glutamate thus accumulates in the extracellular space 
(Benveniste et al., 1984; Hagberg et al., 1985), resulting in the overactivation of 
NMDARs and the further influx of calcium. Neuronal death ultimately ensues, 
when excessive calcium results in the disordered activation a wide range of 
7 
 
calcium dependent enzymes such as proteases, lipases, nucleases as well as 
mechanisms generating highly reactive free radical species (Bennett et al., 1996; 
Choi, 1985; Choi, 1987).   
  
1.1.3.2 Inflammation and Cerebral Edema 
 There is a substantial body of evidence indicating that post-ischemic 
inflammation contributes to the progression of ischemic brain injury as well (Deb 
et al., 2010; Dirnagl et al., 1999). In particular, with the onset of ischemic stroke, 
an inflammatory response will be mounted with the activation of calcium 
dependent second-messenger systems and the increase in free radical species 
(Dirnagl et al., 1999). Activated inflammatory mediators such as neutrophils and 
macrophages could then aggravate ischemic damage by many mechanisms, for 
example by obstructing the microvasculature or by producing toxic mediators 
detrimental to the already injured cells. 
  
Cerebral edema is also another area of concern as it was suggested to 
contribute to much of the death and disability after ischemic stroke (Deb et al., 
2010). Edema after ischemia can take the form of a cytotoxic or a vasogenic 
edema. Cytotoxic edema occurs within minutes to hours, where water enters the 
brain passively due to a larger influx of Na+ and Cl- compared to the efflux of K+ 
(Dirnagl et al., 1999). Vasogenic edema, on the other hand, occurs over hours and 
days, resulting from the influx of water due to the leakage of macromolecular 
serum proteins such as albumin from the blood vessels through the damaged 
8 
 
blood brain barrier. The gradual increase in intracellular fluid and the resulting 
increased intracranial pressure would worsen ischemia and ultimately lead to 
irreversible brain damage and death (Deb et al., 2010). 
 
 1.1.3.3 Production of Reactive Oxygen Species and Apoptosis 
 Reactive oxygen species are generated with the activation of enzymes 
such as proteases, lipases and nucleases early on in the ischemic cascade. These 
reactive oxygen species interact and damage the vascular endothelium, producing 
damaging consequences. In addition, these reactive oxygen species could initiate 
cell death through the apoptotic pathway by means of redox signaling (Deb et al., 
2010). 
 
Neurons that are compromised by excessive glutamate receptor activation, 
calcium overload and reactive oxygen species can either die by necrosis or 
apoptosis (Dirnagl et al., 1999). Neurons at the core of the stroke insult usually 
die by necrosis due to the complete occlusion of blood flow. Neurons within the 
penumbra region, on the other hand, usually die by apoptosis given time and 
without treatment as they are only partially injured due to the presence of 
collateral circulation. In particular, caspases and other pro-apoptotic genes would 
be expressed at higher levels and neurons eventually die by either the death 
receptor pathway (extrinsic pathway) or the mitochondria pathway (intrinsic 
pathway). 
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1.1.4 Treatment strategies for Ischemic Stroke 
The main therapeutic approaches to ischemic stroke usually revolve 
around reperfusion and neuroprotection. Reperfusion drugs are mainly 
thrombolytic agents, antiplatelet agents or fibrinogen depleting agents that aim to 
allow the return of blood flow to the ischemic region. An example is the 
recombinant tissue plasminogen activator (tPA), which is the only drug approved 
by the FDA for the treatment of ischemic stroke to date. Neuroprotective drugs, 
on the other hand, aim to rescue the ischemic penumbra region by interrupting the 
ischemic cascade. Calcium antagonists, sodium channel blockers, glutamate 
antagonists, free radical scavengers and apoptosis inhibitors have been proposed 
to arrest the ischemic cascade at various points, thereby containing the size of the 
initial stroke infarct (Lyden et al., 2000).  
 
1.1.5 Challenges in Translating Treatment Strategies from Bench to   
          Bedside 
 
The search for an effective stroke treatment has been a daunting one thus 
far. Despite the increasing knowledge acquired on the pathophysiological 
mechanisms responsible for neuronal death after ischemic stroke, no effective 
treatment apart from the tPA has been discovered to date. The tPA, though an 
approved drug, is not without limitations. Patients presenting with stroke 
symptoms at the emergency ward could only be administered with tPA after 
undergoing a CT scan to exclude the possibility of a hemorrhagic stroke as 
10 
 
thromolytics could not be administered in that situation. As such, the time delay 
in stroke diagnosis and a therapeutic window of only three hours for the tPA 
meant that only a small percentage of patients would benefit from the drug (Green 
et al., 2006; Lindsberg et al., 2003). Moreover, some patients may not even 
reperfuse after given the drug or risk suffering from hemorrhagic complications. 
Over the years, progress had been made with the demonstration of efficacy when 
tPA was administered within 4.5 hours after ischemic stroke onset (Hatcher et al., 
2011). Nevertheless, more work has to be done, as trials of new perfusion 
enhancing drugs such as abciximab, ancrod and prourokinase yielded 
disappointing results (Green et al., 2006).  
 
The extensive search for effective neuroprotective drugs did not prove to 
be fruitful as well. Though many neuroprotective drugs were able to reduce stroke 
infarct in animal models of stroke, none has proven efficacious in clinical trials 
due to either a lack of efficacy or the occurrence of adverse effects (Table 1-1) 
(Green et al., 2006; Lutsep et al., 2001; Wahlgren et al., 2004). Many reasons 
have thus been suggested to explain the apparent discrepancy between the animal 
studies and the clinical data (Dirnagl et al., 1999; Fischer, 2008; Gladstone et al., 
2002). First, animal studies were often conducted using short time windows 
which were usually not attainable in clinical trials. Time delays in transporting 
patients to hospitals and the diagnosis process resulted in clinical trials using 
longer time window as compared to animal studies. Second, animal studies 
usually focused on the demonstration of efficacy before adverse effects were 
11 
 
assessed. Clinical trials, on the other hand, start with low doses and only increase 
dosages in the absence of side effects. As such, effective doses determined in 
animal testing may not even be attained in humans due to the occurrence of side 
effects. Other reasons that were proposed include inappropriate outcome measures 
used, poor clinical trial design and patient selection. 
 
Table 1-1 Promising neuroprotective compounds tested in acute ischemic stroke trials  
Mechanism of action Compound Clinical trial status Outcome 
Calcium antagonists Nimodipine1 
Flunarizine2 
Nicardipine3  
Phase III trial completed 
Phase III trial completed 





Calcium chelators DP-b994 
 
Phase II trial completed,  
Phase III trial ongoing   
 
Safe 
Sodium channel blockers Fosphenytoin5 
Sipatrigine6 
Lubeluzole7  
Phase III trial completed 
Phase II trial terminated 
Phase III trial completed 
No benefit 
CNS side effects 
No benefit 
 
Competitive NMDAR antagonists 
 








Two Phase III trials abandoned 
 
Phase III trial terminated 
Phase II trial completed 
Phase III trial completed 
No benefit, adverse effects 
 
No benefit, adverse effects 
CNS side effects 
No benefit 
                                                            
1 Stroke 2001; 32(2):461-465  
2 Acta Neurol Scand. 1996; 93(1): 56-60  
3 Clin Ther. 1990; 12(4):344-51 
4 Int J Stroke 2011; 6(4): 362-7  
5 The Internet Stroke Center 2011; http://www.strokecenter.org/trials/interventions?tid=17 
6 Cerebrovasc Dis. 2000; 10(6): 431-6 
7 Stroke 2000; 31(11): 2543-51 
8 Stroke 2000; 31(2): 347-354  
9 JAMA. 2001; 286(21): 2673-2682 





Glycine-site NMDAR antagonists 
 
 









Clinical development abandoned 
Phase II trial completed 
 
Phase III trial completed 
Phase II trial completed 
 
Phase III trials abandoned 
Phase II trial ongoing 
 
 











Phase III trial completed 
Phase III trial completed 
Phase III trial ongoing 





Kappa opioid receptor anatgonists Nalmefene19 
 
Phase III trial completed No benefit 




11Lancet. 2004; 363(9407): 439-45 
12Stroke 1999; 30(9): 1796-1801 
13JAMA. 2001; 285(13):1719-1728  
14Stroke 1999; 30(3):508-513 
15Ann N Y Acad Sci. 1999; 890:42-50 
16Stroke 2008; 39(6): 1751-8 
17Stroke 1998; 29(1): 12-7  
18Stroke 1998; 29(6): 1256-7  










Phase III trial halted 
Phase III trial completed 
 
No benefit 
No benefit, adverse effects 
 
Fibroblast growth factors Trafermin21  Phase II/III trial halted No benefit 
 
Cell membrane stabilizer Citicoline22 Phase III trial completed No benefit 
 
AMPA antagonists YM-8725 
ZK20077523  
Phase II trial abandoned 
Phase IIa trial terminated 
Failed an interim futility analysis 
Adverse effects 
 
GABA agonists Clomethiazole24  Phase III trial completed No benefit 
 
5-hydroxytryptamine 1A agonists Repinotan5 
Piclozotan5 
Phase III trial completed 
Phase II trial terminated 
 
Negative results 
Astrocyte modulating compounds 
 
Arundic acid5 Phase II trial terminated  
 
                                                            
20Neurology 2001; 57(8): 1428-34  
21Cerebrovasc Dis. 2002; 14(3-4): 239-251  
22Neurology 2001; 57(9):1595-602  
23Stroke 2002; 33(12): 2813-8  
24Stroke 1999; 30(1): 21-28  
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1.1.6 Experimental Models of Ischemic Stroke 
Experimental models of ischemic stroke play extremely crucial roles in 
unraveling the intricate biochemical mechanisms leading to ischemic damage 
progression, as well as provide a platform for the testing of neuroprotective 
strategies. Many in vitro and in vivo models have been developed over the years, 
as the search for an ideal model, which researchers believe should incorporate 
clinical relevancy and high reproducibility, intensifies (Hossmann, 1998). In vitro 
models of ischemic stroke include primary neuronal cultures (Goldberg et al., 
1993), organotypic cultures (Vornov et al., 1994) and brain tissue slices 
(Whittingham et al., 1984) that are incubated in deoxygenated and glucose-free 
medium in order to mimic ischemic conditions during stroke. These models 
provide well controlled environments for the study of stroke pathophysiology and 
drug testing. They are however, not without limitations. In particular, the culture 
media in which neurons and brain slices are incubated may differ substantially in 
constituents from the in vivo situation, making the in vitro data less reliable 
(Hossmann, 1998). As such, animal models may at times serve as more 
appropriate models of human stroke. 
 
Animals provide excellent models of ischemic stroke for a number of 
reasons. First, the characteristics of stroke are similar in humans and animals. In 
particular, the phases of ischemic brain damage progression experienced by both 
humans and animals are similar, owing to similar biochemical and molecular 
mechanisms of injury (Fischer, 2008). Second, animals provide intact vasculature, 
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accounting for variable factors such as brain perfusion (Fischer, 2008). Third, 
animal models allow the study of early ischemic events, which may be difficult to 
study in humans due to the delays in stroke diagnosis. Potential drug candidates 
could also be evaluated for their therapeutic and safety profiles, which is usually 
not possible and ethical in clinical trials.  
 
Many animal species have been used in models of ischemic stroke to date, 
notably rodents, cats, gerbils and nonhuman primates. Of them all, rodent models 
are the most commonly used, as laboratory rodents are well-studied, relatively 
inexpensive and readily available. In general, ischemic animal stroke models are 
categorized into global ischemic stroke models and focal ischemic stroke models, 
both of which would be discussed in detail below. 
  
1.1.6.1 Global Ischemic Stroke Models 
 Global ischemic models induce widespread cerebral ischemia, through the 
reduction of blood flow to the entire brain. These models aim to mimic cerebral 
ischemia caused by clinical conditions such as cardiac arrest, severe hypotension, 
or diseases that alter blood flow (Fischer, 2008). Global ischemia in rodents can 
be induced by either a two-vessel or a four-vessel occlusion of the major arteries 
supplying blood to the brain (Table 1-2). In particular, the two-vessel occlusion 
model involves the occlusion of the bi-carotid arteries and the induction of 
hypotension (Fischer, 2008). The four-vessel occlusion model, on the other hand, 
involves the permanent occlusion of the bi-vertebral arteries and the transient 
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occlusion of the bi-carotid arteries (Fischer, 2008). In both models, cerebral blood 
flow is restored after ischemia was induced for about seven to ten minutes, 
followed by injections of epinephrine and chest compression (Fischer, 2008). This 
is similar to the clinical situation of a cardiac arrest, making the models a closer 
approximation to human stroke.  
 
Global ischemia results in widespread brain injury, where neurons in 
vulnerable brain regions such as the cerebral cortex, hippocampus and the 
caudoputamen die from necrosis. Complete cell death, however, was suggested to 
occur over a period of three to seven days, providing a window of opportunity for 
therapeutic strategies to work. Global ischemic models thus provide clinicians and 
researchers with an invaluable tool, enabling them to search for potential 
therapeutic targets, as well as test therapeutic strategies aiming to reduce the size 
of the stroke infarct. 
  
1.1.6.2 Focal Ischemic Stroke Models 
 Focal ischemic models, on the other hand, induce cerebral ischemia in 
specific regions of the brain, depending on the artery which was occluded. There 
are two types of focal ischemic models, namely the multifocal stroke models and 
the focal hemisphere cerebral ischemic stroke models (Fischer, 2008). Multifocal 
stroke models attempt to mimic stroke caused by multiple thrombi, resulting in 
the occurrence of many sites of ischemia. Though these models are relatively 
easily to perform, they are less commonly used due to limited applicability and 
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low reproducibility (Fischer, 2008). Focal hemisphere cerebral ischemic stroke 
models, on the other hand, are more useful as they mimic single site cerebral 
ischemia caused by atherosclerosis, or arterial blockage by a thrombus or an 
embolus. Many of such models have been developed thus far, most of which have 
focused on the middle cerebral artery (MCA). MCA occlusion (MCAO) can be 
induced in several ways, some of which include intraluminal monofilamaent 
occlusion, electrocauterization, endothelin-1 infusion or blood clot/microsphere 
injection (Table 1-2). Irrespective of the method of occlusion, all the techniques 
attempt to block blood flow through the MCA, subjecting brain areas supplied by 
the artery to ischemia.  
 
Ischemic brain damage post-MCAO is characterized into two distinct 
phases; in particular, immediate neuronal necrosis at the core of the stroke insult 
and delayed cell death in the region surrounding the core area (penumbra). 
Neurons at the core of the stroke insult usually undergo immediate cell death, as 
blood flow to the region is completely obstructed. Neurons at the penumbra 
region, however, are often injured but not yet dead, as the presence of collateral 
arteries ensure a limited supply of oxygen and glucose. Cell death at the 
penumbra region is thus thought to be reversible, providing an opportunity for 
therapeutic strategies to contain the size of the initial stroke infarct. Ischemic 
stroke models hence play an important role, by not only allowing a greater 
understanding of the ischemic cascade but by providing a means of drug testing as 
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well. Two of the more commonly used focal hemisphere cerebral ischemic stroke 
models are discussed below.  
 
1.1.6.2.1 The Tamura Model 
 The Tamura model is a model of permanent focal ischemia, induced by 
the unilateral occlusion of the MCA through electrocauterization. It is one of the 
best characterized models commonly used from the late 1980s, and is regarded as 
the gold standard for the testing of neuroprotective agents (O'Neill et al., 2001). 
The model is commonly used as ischemic infarcts to the cortical and striatal 
regions were reproducible and a 100% infarction rate could be obtained when the 
MCA is either occluded from the origin or proximal to the olfactory tract to its 
junction with the inferior cerebral vein (Bederson et al., 1986; Niiro et al., 1996). 
A variation to the surgical procedure that allowed the zygomatic arch to remain 
intact also made the model more robust, reducing its mortality rate. The Tamura 
model, however, has its limitations. In particular, the model may be considered 
relatively invasive with a craniectomy, and does not allow the study of 
reperfusion events which may play a role in brain injury progression in human 
ischemic stroke (O'Neill et al., 2001).  
 
1.1.6.2.2 The Intraluminal Monofilament Suture Model 
 The intraluminal monofilament suture model is a new and relatively 
noninvasive model introduced by Koizumi et al. (1986). The model involves the 
insertion of an intraluminal monofilament through the external carotid artery to 
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the origin of the MCA, blocking blood flow through the MCA as a result. As 
blood flow could be restored by removing the suture, the suture model allows 
either a permanent or a transient occlusion of the MCA. Many variations of the 
model have since been reported, including the use of sutures coated with poly-l-
lysine introduced by Belayev and colleagues (1996). Poly-l-lysine was said to 
increase the adhesive forces of the suture, ensuring reproducible infarcts in the 
cerebral cortex and the striatum (Belayev et al., 1996). Though the suture model 
has the advantage of allowing reperfusion, it has a relatively high mortality rate 
and high risks of damaging the endothelium. 
 
Table 1-2 Animal models of ischemic stroke  
Global Ischemia Focal Ischemia 
Four-vessel occlusion Permanent MCAO (Tamura model) 
Two-vessel occlusion Intraluminal Monofilament MCAO 
 Endothelin-1 MCAO 
 Photochemical MCAO 
 Blood clot MCAO 
 Microsphere MCAO 
 
1.2 The Glutamate Receptor Superfamily  
The glutamate receptor superfamily is divided into two major categories, namely 
the metabotropic receptor family and the ionotropic receptor family (Figure 1-2). 
The metabotropic receptors (mGluRs) are G-protein-coupled receptors, mediating 
slow glutamate responses resulting in eventual long lasting changes in synaptic 
plasticity (Pin et al., 2003). It has eight receptor subtypes which are classified into 
three different groups based on sequence homology, pharmacology and the 
associated G-protein (Figure 1-2) (Pin et al., 2003). In particular, group I is 
linked to phospholipase C-mediated polyphosphoinositide hydrolysis while group 
II and group III negatively couple either to adenyl cyclase or linked to ion 
channels (Pin et al., 2003). The ionotropic receptors (iGluRs), on the other hand, 
are ligand-gated ion channels responsible for fast synaptic transmission 
contributing to information processing, synaptogenesis and learning and memory 
(Dingledine et al., 1999). They are divided into three subclasses, namely the N-
methyl-D-aspartate (NMDA) receptors, the α-amino-3-hydroxy-5-
methylisoxazole-4-propionic acid (AMPA) receptors and the kainic acid (KA) 





Figure 1-2 Overview of the glutamate receptor superfamily. The glutamate 
receptor superfamily is divided into two major subfamilies, the ionotropic 
glutamate receptors and the metabotropic glutamate receptors. The family of 
ionotropic glutamate receptors is divided into NMDA, AMPA and KA receptors 
while the family of metabotropic glutamate receptors is divided into three 





1.2.1 The NMDA Receptor and its Subunits 
The NMDARs are heteromeric complexes comprising of different 
combinations of three subunit subtypes, namely GluN1, GluN2 and GluN3. The 
GluN1 subunit is encoded by a single GRIN1 gene, but alternative splicing of the 
gene resulted in eight different isoforms. In particular, the GluN1-1a isoform is 
the most abundantly expressed. The GluN2 and GluN3 subunits, on the other 
hand, have four (GluN2A-D) and two (GluN3A-B) distinct subtypes respectively, 
each of which has several splice variants (except GluN2A). All the NMDAR 
subunits share similar membrane topology, which is characterized by an 
extracellular ligand binding domain (LBD), an extracellular amino-terminal 
domain (ATD), a transmembrane domain and an intracellular carboxyl-terminal 
domain (CTD) (Figure 1-3).  
 
 
Figure 1-3 Modular structure of the NMDAR subunit. The NMDAR subunits 
share similar membrane topology, consisting of three transmembrane segments 
(M1, M3 and M4), a re-entrant loop (M2), an intracellular carboxyl-terminal 
domain and large extracellular domains consisting of the ligand binding domain 





1.2.1.1 The Extracellular Ligand Binding Domain 
The ligand binding domain (LBD), a highly conserved domain within the 
superfamily of glutamate receptors, is formed by two discontinuous stretches of 
amino acids termed the S1 region, located on the amino-terminal side of 
membrane domain M1, and the S2 region, located between the membrane 
domains M3 and M4 (Figure 1-3) (Traynelis et al., 2010). Glycine binds to the 
LBD of the GluN1 and GluN3 subunits, while glutamate binds to the LBD of the 
GluN2 subunits.  
 
The LBD was previously shown to be structurally related to the bacterial 
lysine arginine ornithine binding protein (LAOBP) (Kuryatov et al., 1994; Laube 
et al., 1997). As such, the binding of glycine and glutamate to their respective 
subunits was proposed to mirror a Venus flytrap model. This model was 
subsequently validated when the crystal structure of the LBD of GluN1 was 
solved by Furukawa and colleagues (2003) through the co-crystallization of the 
GluN1 S1-S2 segment with glycine. Their work showed that the structure of the 
LBD resembled a clamshell, with the agonist binding domain located at the cleft 
of the bi-lobed structure (Furukawa et al., 2003). Binding of glycine or glutamate 
to the GluN1 or GluN2 subunits respectively is believed to trigger movement of 
the clamshell, thereby gating the ion channel and influencing NMDAR activity 





1.2.1.2 The Extracellular Amino-Terminal Domain 
The amino terminal domain (ATD), on the other hand, is formed by the 
first 400 amino acid residues of the subunit protein. The ATD is an important 
binding site for numerous allosteric modulators and plays vital roles in controlling 
receptor functions such as subunit assembly, receptor trafficking and channel 
gating (Hansen et al., 2010; Herin et al., 2004). The ATD of the GluN2 subunits, 
in particular, have been shown to control the pharmacological and kinetic 
properties of the NMDAR (Gielen et al., 2009; Yuan et al., 2009). Agonist 
potency, deactivation time course, open probability and open/shut duration of the 
NMDAR are some of the factors that are dependent on the GluN2 ATD (Yuan et 
al., 2009).  
 
The structure of the ATD had been hypothesized to resemble a clamshell, 
due to its weak homology to the leucine isoleucine valine binding protein 
(LIVBP). This hypothesis was later confirmed by Karakas and colleagues (2009), 
when their work revealed that the GluN2B ATD assumed an overall clamshell-
like architecture composed of two domains, R1 and R2, held together by three 
well-structured loops. A close evaluation of the cleft between the R1 and R2 lobes 
also revealed a zinc binding site, as well as a hydrophobic pocket pivotal in 





Since the discovery that NMDARs exist as tetrameric complexes of 
multiple subunit subtypes, attempts have been made to identify subunit-selective 
antagonists (Paoletti et al., 2007). This led to the discovery of a class of 
compounds known as the phenylethanolamines. Phenylethanolamines exemplified 
by ifenprodil have been shown to be highly selective for the GluN2B subunit. 
Homology modeling studies have previously proposed the binding site of 
ifenprodil and its analogues to be located at the ATD of the GluN2B subunit and 
site-directed mutagenesis studies have identified several residues such as Phe182, 
Phe176 and Asp101 to be critical in conferring their sensitivity (Malherbe et al., 
2003; Mony et al., 2009; Ng et al., 2008; Perin-Dureau et al., 2002). 
Nevertheless, contrary to the consensus view, Karakas et al. (2011) had recently 
reported that the phenylethanolamines bind to the interface of the GluN1 and 
GluN2B ATDs, rather than within the GluN2B ATD cleft itself.   
 
1.2.1.3 The Transmembrane Domains 
The transmembrane domain of the NMDAR subunit does not consist of 
four membrane-spanning segments, an architecture typical of ligand-gated ion 
channels (Wo et al., 1995). It is, instead, made up of three membrane-spanning 
helices (M1, M3 and M4) and a re-entrant loop (M2), resulting in a subunit 
topology consisting of an extracellular ATD and an intracellular CTD (Figure 1-
3). The transmembrane domain of each of the four subunits in the tetrameric 
receptor complex forms the receptor ion channel, which was suggested to share 
structural similarities to the potassium ion channel (Kuner et al., 2003; Wo et al., 
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1995). In particular, the M2 region of the NMDAR subunit bears resemblance to 
the P segment of the potassium ion channel, given that it does not span the 
membrane and may instead be inserted into the channel pore, influencing ion 
permeation (Wo et al., 1995). 
 
The narrow constriction of the NMDAR channel pore is formed by the 
interaction of an asparagine residue located on the GluN1 subunit and two 
asparagine residues located on the GluN2 subunit (Villmann et al., 2007). The 
channel pore is permeable to monovalent cations such as K+ and Na+, but unequal 
contribution of asparagine residues by the different subunits resulted in its 
selective permeability to divalent cations. For example, the NMDARs are 
permeable to Ca2+ but not Mg2+. This lack of permeability to Mg2+ has important 
functional implications, as it allows for a voltage dependent Mg2+ block, a means 
of regulating NMDAR activity (Qian et al., 2002; Wollmuth et al., 2004).   
 
1.2.1.4 The Intracellular Carboxyl-Terminal Domain  
The carboxyl-terminal domain (CTD), among the other domains, is the 
least conserved within the glutamate receptor superfamily (Traynelis et al., 2010). 
Structural details on the CTD have been limited to date, as the CTD shows no 
sequence homology to any known proteins (Traynelis et al., 2010). It was 
however suggested that the CTD sequence encodes for docking motifs, allowing 
for the binding of a variety of intracellular regulatory proteins (Traynelis et al., 
2010). As such, the CTD is thought to play vital roles in receptor regulation such 
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as synaptic protein-protein interactions, membrane targeting and receptor 
turnover, through undergoing phosphorylation and interaction with numerous 
intracellular signaling proteins (Traynelis et al., 2010; Villmann et al., 2007).  
 
1.2.2 Subunit Stoichiometry 
Functional NMDARs exist as tetrameric complexes, composing of two 
GluN1 subunits assembled together with either two GluN2 subunits or a 
combination of GluN2 and GluN3 subunits (Traynelis et al., 2010). The simpler 
assembly of NMDARs would be that composed of two GluN1 subunits assembled 
together with two GluN2 subunits of the same type. Each GluN2 subunit confers 
distinct properties to the NMDAR, influencing factors such as spatial expression, 
channel conductance, and magnesium blockage. In the case of spatial expression, 
GluN2A-containing receptors have been shown to be widely expressed in several 
brain regions, while the expression of GluN2B-containing receptors was restricted 
to forebrain regions such as the cortex and the hippocampus. Glu2C- and 
GluN2D-containing receptors, on the other hand, were mainly expressed in the 
cerebellum and midbrain respectively. Channel conductance and magnesium 
blockage were also different depending on the GluN2 subunit composition. In 
particular, GluN2A and GluN2B-containing receptors generate high conductance 
channel openings with a high sensitivity to block by magnesium (Cull-Candy et 
al., 2001). Glu2C- and GluN2D-containing receptors, in contrast, produce low 
conductance openings with a lower sensitivity to magnesium block (Cull-Candy 
et al., 2001).   
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GluN1 subunits could also assemble with two different subtypes of GluN2 
subunits or with GluN3 subunits to form triheteromeric NMDARs. These 
triheteromeric NMDARs have been reported to be present in several brain 
regions, with GluN1/GluN2A/GluN2B NMDARs observed in the forebrain and 
GluN1/GluN2A/GluN2C NMDARs observed in the cerebellum (Cathala et al., 
2000; Luo et al., 1997). Functional properties of these receptors, however, remain 
unclear and limited pharmacological tools are available to differentiate them from 
the diheteromeric ones.  
 
1.2.3 NMDA Receptor Function and Disease   
The NMDARs regulate fast excitatory synaptic transmission, mediating a 
number of important physiological processes such as learning and memory. 
NMDAR activation requires the fulfillment of two conditions, namely the 
simultaneous binding of agonist glutamate and co-agonist glycine, as well as 
membrane depolarization necessary for the release of the Mg2+ blockage of the 
receptor. Activation of NMDARs in turn results in an influx of Ca2+, necessary 
for the triggering of downstream intracellular signaling events that eventually 
initiate the physiological responses. 
  
Though NMDARs play important physiological roles in the CNS, 
inappropriate activation of NMDARs could result in undesirable disease states 
through calcium overload. Indeed, dysfunction of NMDARs have been implicated 
in several neurological diseases such as stroke, Alzheimer’s disease, Parkinson’s 
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disease, Huntington’s disease, neuropathic pain and amyotropic lateral sclerosis. 
As such, the NMDAR has been one of the main targets for many therapeutic 
strategies to date (Kemp et al., 2002; Martin et al., 2010).  
 
1.3 NMDAR Antagonists in Stroke Treatment 
Irreversible neuronal death resulting from the overstimulation of NMDARs by 
elevated extracellular glutamate level during ischemic stroke suggested that 
blockade of NMDAR activity during the early onset of ischemia would provide a 
means of neuroprotection. Indeed, subsequent preclinical testing of several 
NMDAR antagonists showed consistent reduction in ischemic brain damage 
irrespective of the species or the model of cerebral ischemia used, raising hopes 
that NMDAR antagonism could be an effective therapeutic approach to ischemic 
stroke. As such, many antagonists targeting the different modulatory sites of the 
NMDAR have been developed and tested in clinical trials. These antagonists 
include competitive antagonists of the glutamate binding site, non-competitive 
channel blockers, glycine site antagonists and GluN2B subunit-selective 
antagonists (Madden, 2002; Muir, 2006; Palmer, 2001). However, despite the 
initial enthusiasm, none of these antagonists have proven efficacious in clinical 
testing, either due to a lack of efficacy or the occurrence of undesirable adverse 






1.3.1 Competitive NMDAR Antagonists    
Competitive NMDAR antagonists such as selfotel bind to the glutamate 
binding site of the NMDAR. Selfotel was a promising candidate in preclinical 
studies, as significant neuroprotection was observed when it was tested in 
different models of cerebral ischemia using different animal species such as 
rodents, rabbits and gerbils (Boast et al., 1988; Sauer et al., 1993; Simon et al., 
1990). Subsequent clinical testing, however, yielded disappointing results. In 
particular, two international phase III ischemic stroke trials investigating the 
efficacy of a single dose of selfotel administered to patients admitted within six 
hours of stroke onset were discontinued due to higher mortality observed in the 
selfotel-treated patients (Davis et al., 2000). Adverse effects such as 
hallucinations, agitation and confusion were also more common in the selfotel-
treated group, leading investigators to suggest that selfotel may in fact be 
neurotoxic in brain ischemia (Davis et al., 2000). 
 
1.3.2 Non-competitive NMDAR Channel Blockers 
Non-competitive NMDAR channel blockers, unlike competitive NMDAR 
antagonists, do not compete with glutamate for the agonist binding site, but 
instead act at the channel pore, blocking ionic current through the channel. Many 
channel blockers such as aptiganel, dextrorphan, remacemide, AR-R15896AR 
and magnesium have been developed and tested in clinical trials, but none has 




Aptiganel, a high affinity channel blocker, was initially suggested to be a 
promising neuroprotective agent as it demonstrated pre- and post-ischemic 
efficacy in animal models of stroke (Meadows et al., 1994; Minematsu et al., 
1993). Subsequent phase II clinical testing also generated optimism, as aptiganel 
was shown to be well tolerated in healthy volunteers (Muir et al., 1995a). A large 
randomized controlled phase III trial was thus undertaken to evaluate the clinical 
benefit of aptiganel in ischemic stroke patients admitted within six hours of stroke 
onset. The trials were however prematurely halted due to a lack of efficacy and a 
potential imbalance in mortality (Albers et al., 2001).   
 
In addition to the high affinity channel blockers, low affinity channel 
blockers such as dextrorphan, remacemide and AR-R15896AR were also 
evaluated in clinical trials. In particular, dose ranging studies on dextrorphan, 
remacemide and AR-R15896AR were carried out to determine their safety and 
tolerability in patients with ischemic stroke. Dextrorphan was reported to be well 
tolerated at low doses, but adverse effects similar to that of selfotel were 
encountered at higher doses of the drug (Albers et al., 1995). Large scale testing 
of efficacy was thus never completed. Remacemide and AR-R15896AR suffered 
a similar fate, with tolerability issues encountered at higher dosages (Dyker et al., 
1999; Lees et al., 2001). Remacemide, in particular, was suggested to be 
unsuitable in acute ischemic stroke treatment, due to the lag time it requires to 




Magnesium, in the early stages of preclinical testing, generated much 
enthusiasm as it was shown to be neuroprotective even when given six hours after 
the onset of ischemia (Yang et al., 2000), a time window considerably much 
longer than other neuroprotective agents. Subsequent small pilot trials have also 
suggested potential benefit in patients (Muir et al., 1998; Muir et al., 1995b). 
Nevertheless, despite the initial optimism, large phase III clinical testing of 
magnesium subsequently reported a lack of efficacy, with higher mortality 
observed for the drug-treated group (Muir et al., 2004).    
   
The similar spectrum of adverse events and an imbalance in mortality 
encountered by both competitive antagonists and non-competitive channel 
blockers suggested that complete inhibition of NMDAR activity may not be 
beneficial for stroke treatment and may instead be harmful. Glycine site 
antagonists and subunit-selective antagonists were thus developed and tested, in 
the hope that these compounds would fare better in clinical trials with their better 
side effect profiles. 
  
1.3.3 Glycine Site NMDAR Antagonists 
In addition to agonist glutamate, the binding of co-agonist glycine is also 
required for the activation of NMDARs. As such, glycine site antagonists have 
also been proposed to be potential neuroprotectants. In fact, greater optimism for 
benefit was generated for glycine site antagonists as they were not only 
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neuroprotective in animal models of ischemic stroke, but appear to have a better 
side effect profile as well (Chen et al., 1993; Newell et al., 1995).  
 
Gavestinel is an example of an antagonist highly selective for the glycine 
binding site. Despite showing good tolerability in phase II studies, gavestinel 
failed to show any clinical benefit in subsequent two large randomized controlled 
phase III trials (GAIN Americas and GAIN International) (Sacco et al., 2001). 
The lack of efficacy was disappointing as gavestinel appeared to be promising 
with no serious safety issues observed, a great contrast to previous trials of 
competitive antagonists and channel blockers.  
 
Licostinel is another example of a glycine site antagonist that had 
progressed to clinical testing. Similar to gavestinel, licostinel had no major safety 
issues, and was well tolerated by acute stroke patients in a dose escalation study 
(Albers et al., 1999). Efficacy, however, could not be deduced in the study and 
large scale testing was also never initiated.   
 
1.3.4 GluN2B Subunit-Selective NMDAR Antagonists 
Apart from glycine site antagonists, subunit-selective NMDAR 
antagonists were also proposed to be a safer alternative as they do not cause 
complete synaptic block. Of particular interest are the GluN2B subunit-selective 
antagonists as studies have shown that the GluN2B subunit is the predominant 
subtype in extrasynaptic NMDARs, where their activation was shown to result in 
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a loss of mitochondrial membrane potential and ischemic cell death (Chen et al., 
2008; Hardingham et al., 2002; Liu et al., 2007; Picconi et al., 2006).  
 
Ifenprodil and eliprodil are examples of first generation GluN2B subunit-
selective antagonists shown to be neuroprotective in several animal models of 
cerebral ischemia (Carter et al., 1988). Both compounds, however, are also 
antagonists of α1-adrenergic receptors, serotonin receptors and calcium channels, 
suggesting the possibility of undesirable cardiovascular complications (Gogas, 
2006; Wang et al., 2005). Clinical studies on eliprodil, in fact, have been 
prematurely abandoned due to futility analyses and results have not been 
published. Hence, with the structures of ifenprodil and eliprodil as basic models, 
numerous newer GluN2B subunit-selective antagonists have been developed. 
These antagonists such as CP-101,606 and RO25-6981 have been shown to not 
only have greater selectivity for the GluN2B subunit but also have improved side 
effect profiles (Gogas, 2006; Wang et al., 2005).  
 
1.4 5-Substituted Benzimidazole Derivatives 
Benzimidazole derivatives are a class of heterocyclic aromatic organic 
compounds, with the benzimidazole component consisting of the fusion of a 
benzene and an imidazole ring. This class of compounds has been relatively well 
studied, notably for their anti-microbial (Ansari et al., 2009a; Ansari et al., 2009b; 
Kus et al., 2009; Ozkay et al., 2011; Vinodkumar et al., 2008), anti-inflammatory 
(Gaba et al., 2010; Lazer et al., 1987)  and anti-cancer properties (Refaat, 2010; 
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Romero-Castro et al., 2011; Shaharyar et al., 2010). The benzimidazole 
derivatives have also been reported to have an antagonistic effect on NMDAR 
activity, where two classes of 5-substituted benzimidazole derivatives 
(benzylpiperidine benzimidazoles and the phenoxyphenyl benzimidazoles) have 
been shown to exert potent antagonism of the GluN2B subunit-containing 
NMDARs (McCauley et al., 2004).   
 
 The development of the benzylpiperidine benzimidazoles and the 
phenoxyphenyl benzimidazoles as potent GluN2B subunit-selective NMDAR 
antagonists by McCauley et al. (2004) began with the identification of a 
benzimidazole that contains a benzylpiperidine substituent in common with a 
number of published GluN2B subunit-selective compounds such as ifenprodil 
(Figure 1-4). This benzylpiperidine benzimidazole however, had modest GluN2B 
activity and comparable hERG channel and α1-adrenergic receptor binding. 
Hence, an analogue synthesis was carried out to prepare a series of substituted 
benzimidazoles on the basis of this benzylpiperidine benzimidazole, and it 
subsequently led to the synthesis of the phenoxyphenyl benzimidazoles. With 
modifications on the benzimidazole and the pendent phenyl ring, McCauley and 
colleagues (2004) developed benzylpiperidine and phenoxyphenyl 
benzimidazoles that not only exert high affinity antagonism of the GluN2B 
subunit-containing NMDARs, but also showed reduced hERG-channel activity 
and α1-adrenergic binding. The high affinity inhibition of GluN2B subunit-
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selective NMDARs, in particular, has been suggested to be a result of slower 
receptor dissociation kinetics of these benzimidazoles (Kiss et al., 2005). 
 
McCauley and colleagues (2004) had also evaluated the efficacy of the 
benzylpiperidine and the phenoxyphenyl benzimidazoles in the carrageenan-
induced mechanical hyperalgesia assay in rats as well as their pharmacokinetic 
properties in rats and dogs. In particular, phenoxylphenyl benzimidazole N-[2-(4-
phenoxybenzyl)benzimidazol-5-yl]methanesulfonamide (compound 17a) was 
shown to exhibit excellent oral bioavailability in rats but lacked efficacy in the 
carrageenan-induced mechanical hyperalgesia assay due to poor brain penetration. 
The benzylpiperidine benzimidazole 2-{[4-(2-fluorobenzyl)piperidin-1-
yl]methyl}benzimidazole-5-ol (compound 37a), on the other hand, demonstrated 
good pharmacokinetic properties in dogs and good efficacy in the carrageenan-
induced mechanical hyperalgesia assay with an iv dosing protocol. 
 
In view of the high affinity antagonism of the GluN2B subunit-containing 
NMDARs by these benzimidazoles, our laboratory had also attempted to 
characterize the inhibitory profile of two of these benzimidazoles, namely the 
benzylpiperidine benzimidazole N-{2-[(4-benzylpiperidin-1-
yl)methyl]benzimidazol-5-yl}methanesulphonamide (named XK1, Figure 1-4) 
and the phenoxyphenyl benzimidazole N-[2-(4-phenoxybenzyl)benzimidazol-5-
yl]methanesulfonamide (named XK2; Figure 1-4). In that study, XK1 and XK2 
were shown to inhibit GluN1/GluN2B receptors through the GluN2B ATD and 
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their inhibition was shown to be pH-dependent. In addition, it was demonstrated 
in the study that both benzimidazoles were potent in reducing NMDA-induced 
neuronal death in an in vitro excitotoxicity model (Wee et al., 2010). The 
neuroprotective properties demonstrated in vitro coupled with the reduced hERG-
channel activity and α1-adrenergic binding observed for these benzimidazoles 
suggested that 5-substituted benzimidazole derivatives may be effective stroke 
neuroprotectants with minimal adverse effects. No studies, however, have yet 
been undertaken to evaluate their effects in ischemic stroke. 
 
1.5 Hypothesis and Objectives of Study 
We hypothesize that 5-substituted benzimidazole derivatives are effective stroke 
neuroprotectants in vivo. Hence, the primary objectives of this study are to: 
 
1) Characterize the in vitro inhibitory profile of another benzylpiperidine 
benzimidazole 2-{[4-(2-fluorobenzyl)piperidin-1-yl]methyl}benzimidazole-5-ol 
(YY1) 
In addition to XK1 and XK2, benzylpiperidine benzimidazole 2-{[4-(2-
fluorobenzyl)piperidin-1-yl]methyl}benzimidazole-5-ol (named YY1, Figure 1-
4) was previously shown to demonstrate excellent activity in a carrageenan-
induced mechanical hyperalgesia assay in rats and good pharmacokinetic 
behavior in dogs by McCauley and colleagues (2004). As such, we would like to 
characterize the inhibitory profile of YY1, evaluating its neuroprotective 
properties in vitro, determining its mode of inhibition as well as docking it into 
the crystal structure of the GluN2B ATD. 
 
2) Evaluate the in vivo neuroprotective potential of YY1 and XK2 
We would also like to evaluate the neuroprotective potentials of YY1 
(benzylpiperidine benzimidazole) and XK2 (phenoxyphenyl benzimidazole) in a 
rat model of permanent cerebral ischemia, using infarct volume and neurological 









sulfonamide benzylpiperidine phenoxyphenyl 
 YY1 
                                
XK2 
 
Figure 1-4 GluN2B subunit-selective antagonists. The chemical structures of 
ifenprodil and 5-substituted benzimidazole derivatives XK1, XK2 and YY1 are 
shown above. All four compounds have similar structural features, consisting of a 
hydrophobic side chain (highlighted in red) and a hydrogen bond donor group 
(highlighted in green) at both ends of their structures. The benzimidazole 
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2.1 Objectives of Chapter 
The inhibition of GluN1/GluN2B receptors by benzylpiperidine benzimidazole 
XK1 and phenoxyphenyl benzimidazole XK2 was previously characterized by 
our laboratory (Wee et al., 2010). In that report, XK1 and XK2 were shown to 
reduce NMDA-induced neuronal death in an in vitro neuronal excitotoxicity 
model, suggesting their neuroprotective properties in vitro. The GluN2B subunit 
ATD was also shown to confer sensitivity to XK1 and XK2. The inhibition of 
GluN1/GluN2B receptors by benzylpiperidine benzimidazole YY1, however, has 
not been characterized yet. Hence, in this chapter, we attempted to (i) demonstrate 
any neuroprotective effects of YY1 in vitro using the neuronal excitotoxicity 
model, as well as (ii) determine the domain critical for its inhibitory activity using 
the two-electrode voltage clamp on Xenopus oocytes heterologously expressing 
the GluN1/GluN2B receptors (Figure 2-1). 
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2.2 Materials and Methods 
 
2.2.1 Materials 
Trypsin, trypsin inhibitor type II-S, deoxyribonuclease, magnesium sulfate, 
cytosine-ß-D-arabino-furanoside, 3-amino-benzoic acid ethylester, calcium 
chloride, sodium chloride, sodium bicarbonate, potassium chloride, glycine, L-
glutamic acid, barium chloride, HEPES, sodium pyruvate, Hanks’ balanced salts, 
bovine serum albumin, dimethyl sulfoxide, fetal bovine serum, penicillin-
streptomycin, poly-D-lysine, collagenase, from Clostridium histolyticum and 
ifenprodil were obtained from Sigma (St. Louis, MO, USA); Neurobasal medium 
and B27 from Invitrogen (Carlsbad, CA, USA); GlutaMAX-1 and gentamycin 
from Gibco (Carlsbad, CA, USA); NMDA, AP5 and MK-801 from Tocris 
(Ellisville, MO, USA).  
 
The NMDAR subunits previously referred to as ‘NR1’, ‘NR2A’, ‘NR2B’, 
‘NR2C’ and ‘NR2D’ are now known as GluN1, GluN2A, GluN2B, GluN2C and 
GluN2D respectively (Alexander et al., 2008; Collingridge et al., 2009). cDNAs 
encoding the splice variant GluN1-1a (GenBank accession number U11418, 
referred to as GluN1 in this thesis) as well as GluN2B (GenBank accession 
number U11419) subunits were generously provided by Professor S. F. 
Heinemann (Salk Institute, La Jolla, CA, USA). The GluN2BΔM394 construct 




2.2.2 Preparation of YY1 and XK2  
XK2 (N-[2-(4-phenoxybenzyl)benzimidazol-5-yl]methanesulfonamide) was 
prepared via the conventional EDC coupling method as described by Wee et al. 
(2010). YY1 (2-{[4-(2-fluorobenzyl)piperidin-1-yl]methyl}benzimidazole-5-ol), 
on the other hand, was prepared as described by McCauley et al. (2004), with 
several modifications (Figure 2-2). In particular, 4-(2-fluorobenzyl)piperidine 
hydrochloride salt (1a, 4.361 mmol) was added to a solution of DiEA (0.347 mL, 
2 mmol) and ethyl bromoacetate (0.111 mL, 1 mmol)  in DMF (4 mL). The 
reaction was allowed to stir at room temperature for 1 hour before dissolving in 
diethyl ether (30 mL). The solution was then washed with brine (50 mL) followed 
by water (50 mL). The organic phase was dried using MgSO4, concentrated in 
vacuo and purified using column chromatography to yield the pyrimidine ethyl 
ester as a clear syrup (1.06 g, 87% yield). The syrup was dissolved in HCl (6 N, 6 
mL) and the suspension heated at 100oC for 1 hour. The reaction was then 
concentrated in vacuo to yield the corresponding carboxylic acid HCl salt, 1b as a 
white solid (quantitative yield). 1b (1.09 g, 3.79 mmol) was dissolved in DMF 
(37.9 mL), and 4-methoxy-o-phenylenediamine (523.9 mg, 3.79 mmol), 2-chloro-
1-methyl-pyridinium iodide (1.70 mg, 4.93 mmol), TEA (2.11 mL, 15.18 mmol) 
and DMAP (92.6 mg, 0.75 mmol) were added. The reaction was stirred at 50oC 
for 1 hour, dissolved in EtOAc (100 mL) and washed with brine (200 mL) 
followed by 3 x 200 mL water. The organic phase was dried over MgSO4 and 
concentrated in vacuo to yield a dark syrup which was dissolved in glacial acetic 
acid (6 mL) and heated to 140oC for 15 minutes. The reaction was allowed to cool 
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and the acetic acid was removed azetropically using toluene to yield a dark brown 
syrup. The syrup was purified using column chromatography (gradient elution 
2:1:1 EtOAc/Acetone/Hexane to 2:1:1 Acetone/EtOAc/Hexane) to yield a light 
brown solid, 1c (682.3 mg, 51%). 1c (682.3 mg, 1.93 mmol) was dissolved in 
acetic acid (2 mL) and 48% HBr (2 mL) was added to the solution. The solution 
was then heated to 150oC under sealed tube microwave condition for 15 minutes. 
After which the reaction was carefully neutralized to pH 7 using 20% KOH 
solution to yield a suspension with brown precipitate. The suspension was 
extracted with EtOAc (2 x 30 mL) and the combined organic extract was 
concentrated in vacuo to a brown residue which was purified using column 
chromatography (1% TEA in 1:20 MeOH/DCM) to yield a clear syrup, YY1 (526 
mg, 80% yield). YY1 was determined to be at least 97% pure by 1H NMR: 
(CDCl3, 500 MHz) with characteristics as follows: δ 7.32 (d, 1H),  7.11-6.91 (m, 
5H), 6.80 (d, 1H), 3.71 (s, 2H), 2.86 (d, J = 9.4 Hz, 2H), 2.46 (d, J = 5.0 Hz, 2H), 
2.07 (t, J = 10.0, 2H),   1.52 (m, 2H), 1.28-1.24 (m, 3H); 13C NMR (CDCl3, 125 
MHz): δ 162.0, 160.1, 153.7, 131.3, 131.3, 127.6, 127.5, 127.0, 126.9, 123.7, 
123.6, 115.1, 114.9, 112.8, 56.0, 53.8, 45.8, 36.1, 35.5, 31.5, 30.8, 9.1; Nominal 
Mass (LC-MS) (ESI) [M+H]+: calculated for C20H23FN3O+ : 340; found 340. YY1 
was converted to a hydrochloride salt by dissolving in hot ethanol (10 mL) and 
37% HCl (514 µL) was added. The solution was then allowed to stir at room 
temperature for 10 minutes. HCl salt was then carefully precipitated out of the 
solution using hexane (3 mL). The chemical syntheses of YY1 and XK2 













Figure 2-2: Chemical synthesis of YY1. Reagents and conditions: (a) ethyl 
bromoacetate, N,N-diisopropylethylamine, dimethylformamide, room temperature 
condition, 1 hour; (b) 6 N HCl, 100˚C, 1 hour; (c) 4-methoxy-o-phenylenediamine, 
Mukaiyama’s reagent (2-chloro-1-methyl-pyridinium iodide), 4-
dimethylaminopyridine, triethylamine, anhydrous dimethylformamide, 50˚C,1 
hour; (d) glacial acetic acid, 140˚C, 15 minutes; (e) 48% hydrogen bromide/acetic 










2.2.3 Preparation of Cerebrocortical Neuronal Culture 
Pregnant adult Sprague-Dawley rats were sacrificed with an overdose of CO2 
followed by cervical dislocation. Primary cultures of cerebrocortical neurons were 
obtained from 18-day-old Sprague Dawley rat embryos as described by Cheung et 
al. (1998) with modifications. Cortices were aseptically dissected from the brains. 
The meninges and the thoroid plexus were carefully removed under a dissecting 
microscope (Nikon SMZ645, Japan) and placed in a Class I laminar flow hood. 
Cortical tissues were digested in trypsin (0.2 mg/mL) and deoxyribonuclease (40 
μg/mL) in Hank’s balanced salts solution (HBSS) supplemented with glucose (7.4 
mM), sodium pyruvate (1 mM), HEPES (10 mM), NaHCO3 (4.2 mM), MgSO4 
(1.2 mM) and bovine serum albumin (0.3% w/v) at 37°C for 5 minutes followed 
by mechanical trituration. Dissociated cells were harvested by centrifugation and 
resuspended in Neurobasal medium supplemented with FBS (10% v/v), B27 (2% 
v/v), GlutaMAX-1 (0.25% v/v) and penicillin-streptomycin (1% v/v). Cells were 
seeded at densities of 0.5x106 cells/cm2 in 24-well plates (Nunc, Denmark) coated 
with poly-D-lysine (0.1 mg/mL) and cultured at 37°C in a humidified 5% CO2 
incubator. Culture medium was replaced with the above Neurobasal medium and 
their supplements but in the absence of FBS a day later. Cytosine-ß-D-arabino-
furanoside (10 μM) was added on day-in-vitro (DIV) 4 and the cultures were used 






2.2.4 NMDA-Mediated Neuronal Excitotoxicity 
Cerebrocortical neurons (DIV10-11) were treated with NMDA (500 μM) in 
Neurobasal medium (free of serum and supplements) for 3 hours at 37°C in 5% 
CO2 incubator. All drugs and control treatments were prepared in Neurobasal 
medium. MK-801 (10 μM), ifenprodil (10 μM), AP5 (200 μM), YY1 (0.0001-10 
μM) and XK2 (0.0001-1 μM) were added simultaneously with or without 
NMDA-containing medium to the neurons and incubated for 3 hours. The 
viability of cells was then analyzed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. 
 
2.2.5 MTT Cell Viability Assay 
The MTT reduction assay was performed as described by Cheung et al. (2004). 
Briefly, after drug treatment, MTT was added to the neurons and incubated for 30 
minutes at 37°C in 5% CO2. The formazan crystals formed were then dissolved in 
100% DMSO. Absorbance readings were taken using a 96-well plate reader at 
562 nm (SpectraMAX Gemini EM, Molecular Devices, USA). Each cell survival 
assay was performed in triplicate and repeated at least three times on neurons 
harvested from separate pregnant rats. 
 
2.2.6 Expression of GluN1/GluN2B Receptors in Xenopus Oocytes 
cRNAs were synthesized from linearized template cDNA according to 
manufacturer’s specifications. The quality of the synthesized cRNA was assessed 
by 0.6% agarose gel electrophoresis, and the concentration was determined by 
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spectrophotometry. Stage V and VI oocytes were surgically removed from the 
ovaries of Xenopus laevis anesthesized with 3-amino-benzoic acid ethylester (1 
g/L). Clusters of oocytes were incubated with collagenase, from Clostridium 
histolyticum (2 mg/mL) for 2 hours in Ca2+-free solution (composition in mM: 
NaCl 88, NaHCO3 2.4, KCl 1, MgSO4,0.82 and Tris/HCl 5, pH 7.4) with slow 
agitation to remove the follicular cell layer. Oocytes were then washed 
extensively in the same solution supplemented with CaCl2 (0.41 mM) and 
maintained in Barth’s solution comprising of (in mM): NaCl 88, KCl 1, NaHCO3 
2.4, HEPES 15, MgSO4 0.81, Ca(NO3)2 0.32 and CaCl2 0.41 and supplemented 
with gentamycin (0.1 mg/mL) and penicillin-streptomycin (5% v/v). Oocytes 
were injected under the magnification of a Nikon SMZ645 dissecting scope 
(Nikon, Japan) within 24 hours of isolation with 15-20 ng of cRNAs in a 50 nL 
volume using oocyte microinjection pipettes (Drummond Scientific Co., Broomall, 
PA, USA) mounted on a Marzhauser MM33 micromanipulator (SDR, Australia). 
The ratios of GluN1 to GluN2Bwt and GluN1 to GluN2BΔM394 injected cRNAs 
were 3:7 and 1:8 respectively. The injected oocytes were incubated in Barth’s 
solution at 17°C for 3-7 days.  
 
2.2.7 Two-Electrode Voltage Clamp Electrophysiology 
Two-electrode voltage clamp recordings on oocytes were performed as described 
previously (Wee et al., 2010). Oocytes were placed in a dual-track recording 
chamber with a single perfusion line that split to perfuse two oocytes. Recordings 
were conducted 2-3 days post-injection at room temperature using Warner model 
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OC-725C two-electrode voltage clamps (SDR Clinical Technology, Australia) as 
recommended by the manufacturer. The bath clamps communicated across Ag-
AgCl2 pellets (Warner Instruments Corp., Hamden, CT, USA) were placed on 
each side of the recording chamber, and were assumed to be at a reference 
potential of 0 mV. The recording solution contained (in mM): NaCl 90, KCl 1, 
HEPES 10, BaCl2 0.5, pH adjusted to 7.3 with NaOH (5 N). Solution exchange 
was computer-controlled through 8-modular valve positioned (Digital MVP Valve, 
Reno, NV, USA) using the EasyOocyte software (a gift from Professor Stephen F. 
Traynelis, Emory University, Atlanta, GA, USA). Voltage and current electrodes 
were filled with KCl (0.3-3.0 M), and current responses were recorded at a 
holding potential of -50 mV; glutamate (100 μM), glycine (100 μM) and YY1 
(0.001-10 μM) were used in all oocyte experiments unless otherwise stated. 
Experimental manipulations were expressed as a % of the pre-event control 
response, and the data were pooled. YY1 inhibition data were fitted (least square 
criterion) to the equation: 
                 % Response = (100 - minimum)/ (1 + ([antagonist]/IC50)n) + minimum 
where n is the Hill slope, IC50 is the nominal concentration of YY1 that produces 
50% inhibition, and minimum is a residual current response.  
 
2.2.8 Data and Statistical Analyses   
The amplitudes of currents recorded from oocytes were measured using 
EasyOocyte. All data were analyzed and plotted using the GraphPad software. 
Dose-response curves were fitted with a maximum of 100% and a slope factor of 
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1. All data were analyzed using one-way analysis of variance (ANOVA) followed 
by post hoc Tukey test unless otherwise stated. Values of P<0.05 were considered 




























2.3.1 YY1 reduced NMDA-induced neuronal death  
The neuroprotective effects of YY1 in vitro were evaluated in a neuronal 
excitotoxicity model using primary cerebrocortical neurons. These cerebrocortical 
neurons were cultured from E18 Sprague Dawley rat embryos and subsequently 
incubated with NMDA for three hours at DIV10-11 to induce excitotoxicity and 
neuronal death. The neuroprotective potential of YY1 was thus assessed by its 
ability to protect these neurons from the NMDA-induced neuronal death.  
 
As shown in Figure 2-3, incubation of cerebrocortical neurons with 
NMDA (500 μM) elicited on average 53% of neuronal death (P<0.01) as 
determined by the MTT cell viability assay. The concentration of NMDA used 
was well-established (Eliasson et al., 1997; Hasegawa et al., 1998; Wee et al., 
2010) and the observed neuronal death was in agreement with that obtained by 
other studies (Dawson et al., 1991). Open channel blocker MK-801 (10 μM), 
GluN2B subunit-selective non-competitive antagonist ifenprodil (10 μM) and 
competitive antagonist AP5 (200 μM) were used as positive controls in the study. 
These drugs were simultaneously added with or without NMDA-containing 
medium and the viability of the neurons analyzed.  NMDA-induced neuronal 
death was shown to be completely reversed in the presence of MK-801, ifenprodil 
and AP5 (P<0.001; Figure 2-3), while these NMDAR antagonists alone did not 
























































Figure 2-3 Neuroprotection of rat primary cerebrocortical neurons against 
neuronal death by NMDAR antagonists. Cerebrocortical neurons were cultured 
from E18 Sprague Dawley rat embryos and incubated with NMDA (500 μM) at 
DIV 10-11. NMDA elicited on average 53% of neuronal death (F = 10.48, 
##P<0.01, compared with -NMDA, -MK-801, -ifenprodil, -AP5) which was 
reversed completely in the presence of MK-801(10 μM), ifenprodil (10 μM) and 
AP5 (200 μM) (F = 10.48, ***P<0.001, compared with +NMDA). The NMDAR 
antagonists alone did not affect neuronal viability (F = 10.48, P>0.05, compared 
with -NMDA, -MK-801, -ifenprodil, -AP5). Analysis by one-way ANOVA, 
followed by post hoc Tukey test. Data are the mean of three independent 
experiments on cerebrocortical neuronal cultures harvested from three separate 










The neuroprotective effects of XK2 and YY1 were next evaluated. 
Though the neuroprotective effects of XK2 had been previously demonstrated by 
our laboratory (Wee et al., 2010), the experiment was repeated in this study so as 
to allow for a comparison of potency with YY1. Briefly, cerebrocortical neurons 
were incubated with varying concentrations of XK2 or YY1 with or without the 
presence of NMDA (500 μM) in the medium for three hours and the viability of 
the neurons analyzed.  Figures 2-4A and 2-4B show that XK2 and YY1 reduced 
NMDA-induced neuronal death in a concentration-dependent manner. XK2 
yielded an IC50 value of 1.2 ± 0.04 nM (n=3), which was in agreement with that 
previously obtained by our laboratory (Wee et al., 2010). YY1, on the other hand, 
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Figure 2-4 YY1 reduced NMDA-induced neuronal death dose-dependently. 
Varying concentrations of XK2 or YY1 were added to cerebrocortical neurons 
with or without the presence of NMDA (500 μM) in the medium and incubated 
for 3 hours. XK2 (A) and YY1 (B) reduced NMDA-induced neuronal death in a 
concentration-dependent manner (XK2: F = 20.9; YY1: F = 39.29, ***P<0.001, 
compared with +NMDA). XK2 showed a higher potency than YY1 in reversing 
neuronal death (compared at XK2 10 nM, ***P<0.001 and YY1 10 nM, P>0.05). 
Analysis by one-way ANOVA, followed by post hoc Tukey test. Data are the 
mean of three independent experiments on cerebrocortical neuronal cultures 
harvested from three separate pregnant rats. Triplicates per concentration tested 





2.3.2 The ATD of the GluN2B subunit confers sensitivity to YY1 
The neuroprotective effect of YY1 observed in the neuronal excitotoxicity model 
was most likely mediated through the inhibition of GluN2B subunit-containing 
NMDARs. It would thus be useful to characterize the inhibition of 
GluN1/GluN2B receptors by YY1. In particular, it would be important to identify 
the NMDAR subunit domain which is critical for its inhibition.   
 
The GluN2B ATD was previously demonstrated by our laboratory to 
confer sensitivity to the inhibitory activities of XK1 and XK2 (Wee et al., 2010). 
As such, we hypothesized that the GluN2B ATD would most likely be the domain 
involved in the inhibition of GluN1/GluN2B receptors by YY1 as well. To 
determine if the GluN2B ATD confers sensitivity to the inhibitory activity of 
YY1, the ATD (Gln29 to Arg393) of the GluN2B subunit was truncated (mutant 
named as GluN2BΔM394, Figure 2-5) and the inhibition of 
GluN1/GluN2BΔM394 receptors by YY1 was assessed. Briefly, GluN1 and 
GluN2Bwt or GluN1 and GluN2BΔM394 subunits were expressed in Xenopus 
oocytes, and NMDA currents were induced by saturating concentrations of L-
glutamate (100 μM) and glycine (100 μM). The inhibition of agonist-induced 
currents by YY1 in GluN1/GluN2Bwt and GluN1/GluN2BΔM394 receptors was 
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Figure 2-5 Truncation of the GluN2B subunit ATD. Schematic representations 
of the GluN2Bwt and ATD truncated GluN2B subunits are shown above. The 
region Gln29 to Arg393 encoding for the ATD was deleted, and the mutant 
subunit was named GluN2BΔM394. N denotes the N-terminal, C denotes the C-
terminal, S1 and S2 denote the ligand binding domain, M1, M3 and M4 denote 








Figures 2-6A and 2-6B show the representative current traces recorded 
from Xenopus oocytes co-expressing the GluN1/GluN2Bwt and 
GluN1/GluN2BΔM394 receptors respectively. Increasing concentrations of YY1 
was shown to progressively inhibit the current induced by saturating 
concentrations of glutamate and glycine in GluN1/GluN2Bwt receptors (Figure 
2-6A). Inhibition of the agonist-induced current, however, was abolished with the 
truncation of the ATD in GluN1/GluN2BΔM394 receptors (Figure 2-6B). A plot 
of the inhibition-concentration curves yielded an IC50 value of 108 ± 10 nM 
(n=11) for the inhibition of GluN1/GluN2Bwt receptors (Figure 2-7). The IC50 
value for the inhibition of GluN1/GluN2BΔM394 receptors, however, could not 
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Figure 2-6 Inhibition of agonist-induced current by YY1 was abolished with 
the truncation of the ATD. GluN1 and GluN2Bwt, and GluN1 and 
GluN2B∆M394 (ATD truncated GluN2B) subunits were expressed in Xenopus 
oocytes, and NMDA currents were induced by saturating concentrations of 
glutamate (100 μM) and glycine (100 μM). Representative current traces recorded 
from Xenopus oocytes co-expressing the GluN1/GluN2Bwt (A) and 
GluN1/GluN2BΔM394 (B) receptors are depicted above. The grey line denotes 
the application of saturating concentrations of glutamate and glycine, and the 
discontinued black lines denote the application of increasing concentrations of 
YY1. Truncation of the GluN2B ATD was shown to completely abolish the 
inhibition of agonist-induced current by YY1. Calibration: current in μA (y-axis) 
































Figure 2-7 The ATD of the GluN2B subunit confers sensitivity to YY1. YY1 
inhibition curves for GluN1/GluN2Bwt and GluN1/GluN2BΔM394 receptors are 
plotted above. The % maximal response represents the percentage of current 
measured at each YY1 concentration over the maximum current induced by 
saturating concentrations of glutamate and glycine. The mean IC50 value for the 
inhibition of GluN1/GluN2Bwt receptors by YY1 is 108 ± 10 nM. The IC50 value 
for the inhibition of GluN1/GluN2B∆M394 receptors, however, could not be 
determined within the antagonists’ concentration range studied. Each point on the 










In this chapter, we investigated YY1 for its neuroprotective properties in 
vitro as well as determine the domain critical for its inhibition of GluN1/GluN2B 
receptors for neuroprotection. The in vitro neuroprotective effect of YY1 was 
evaluated using rat primary cerebrocortical neurons, where the neurons were 
subjected to NMDA to mimic the clinical situation of excitotoxicity during 
cerebral ischemia. The cerebrocortical neurons used were a model of 
physiological relevance, as they partially retain the developmental sequence of 
NMDA receptor expression in the developing rat brain (Zhong et al., 1994). The 
neuroprotective effect of YY1 was also evaluated at DIV 10-11, a time period 
where GluN2B mRNA levels would have stabilized (Cheng et al., 1999).  
 
The present results demonstrated that YY1 was neuroprotective in the 
neuronal excitotoxicity model, reducing NMDA-induced neuronal death in a 
dose-dependent manner. In comparison to XK2, YY1 was approximately 13-fold 
less potent as a neuroprotectant, in good agreement with that reported by 
McCauley and colleagues (2004) using stably transfected L(tk-) cells expressing 
the human GluN1/GluN2B receptors (~13 fold). YY1 was nevertheless more 
potent when compared to other GluN2B subunit-selective antagonists, most of 
which have IC50 values in the hundreds of nanomolar range (Fischer et al., 1997; 
Gill et al., 2002). The low nanomolar IC50 value of YY1 obtained in the 
excitotoxicity model was in agreement with its high affinity inhibition of 
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GluN1/GluN2B receptors previously reported by other studies (Kiss et al., 2005; 
McCauley et al., 2004).  
 
The efficacy of YY1, XK1 and XK2 in the neuronal excitotoxicity model 
suggested a role of the GluN2B subunit in excitotoxic neuronal death. Indeed, 
Cheng et al. (1999) had previously associated the GluN2B subunit with the 
development of susceptibility to excitotoxicity in cultured neurons, with the 
demonstration that the increase in GluN2B mRNA correlated with the increase in 
glutamate-stimulated changes in calcium concentration and neuronal injury. The 
GluN2B subunit was also shown to be the predominant subtype in extrasynaptic 
NMDARs, where their activation was shown to result in a loss of mitochondrial 
membrane potential and eventually ischemic cell death (Chen et al., 2008; 
Hardingham et al., 2002; Liu et al., 2007; Picconi et al., 2006). 
 
The domain with which YY1 mediates its inhibitory effect was next 
determined using the two electrode voltage clamp on Xenopus oocytes 
heterologously expressing the GluN1/GluN2B receptors. The GluN2B ATD was 
previously shown by our laboratory to confer sensitivity to the inhibition of 
GluN1/GluN2B receptors by XK1 and XK2 (Wee et al., 2010). Hence, to 
determine if the GluN2B ATD confers sensitivity to the inhibition of 
GluN1/GluN2B receptors by YY1 as well, the ATD of the GluN2B subunit was 
truncated and the effect on inhibition by YY1 was assessed. Recordings of 
oocytes expressing the GluN1/GluN2Bwt receptors showed that increasing 
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concentrations of YY1 progressively inhibited the NMDA current induced by 
saturating concentrations of glutamate and glycine. Inhibition of NMDA current 
was however abolished in oocytes expressing the GluN1/GluN2BΔM394 
receptors, suggesting a vital role of the GluN2B ATD in the high affinity YY1 
inhibition. The GluN2B ATD, in fact, had also been demonstrated to confer 
sensitivity to other GluN2B subunit-selective antagonists such as the 
phenylethanolamines (Rosahl et al., 2006). In particular, Rosahl and colleagues 
(2006) performed well-designed experiments to show that the replacement of the 
GluN2B ATD with a chimeric GluN2A/B cDNA in a mouse model resulted in a 
reduction in the sensitivity of ifenprodil and CP-101,606.  
 
The important role of the ATD in the inhibitory activities of YY1, XK1 
and XK2 was not surprising as it has been well established that the ATD of 
GluN2 subunits functions as a modulatory domain in NMDARs (Hansen et al., 
2010; Herin et al., 2004; Yuan et al., 2009). In particular, studies using ATD 
deletion mutants of GluN2A, GluN2B, GluN2C, GluN2D or GluN2 chimeras 
have shown that the ATD controls the pharmacological and kinetic properties of 
the NMDAR, influencing properties such as agonist potency, deactivation time 
course, open probability and mean open/shut durations (Yuan et al., 2009).  
  
Perin-Dureau et al. (2002) had suggested two hypotheses that could 
account for the important role of the GluN2B ATD in receptor modulation by 
GluN2B selective antagonists. The first hypothesis was that the GluN2B ATD 
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contains or forms part of the binding site of the subunit-selective antagonists. The 
second hypothesis was that the GluN2B ATD does not contain the binding site 
but is involved in the transduction mechanism that links the antagonist binding to 
receptor inhibition. Subsequent functional studies using homology modeling and 
site-directed mutagenesis supported the former hypothesis (Malherbe et al., 2003; 
Mony et al., 2009; Ng et al., 2008), and a consensus view that GluN2B subunit-
selective antagonists such as ifenprodil and RO 25-6981 bind to the GluN2B ATD 
emerged. The putative binding site of these antagonists have since been mapped 
to the central cleft of the ATD, and several residues lining the regions of the cleft 
have been identified to be critical to receptor inhibition. The crystal structure of 
the GluN2B ATD was recently elucidated by Karakas et al. (2009). Hence, in the 
next chapter, we attempted to dock YY1 into the central cleft of the GluN2B ATD 
crystal structure, examining the binding conformation of YY1 with respect to the 
cleft residues previously identified to be critical as well as identify new residues 
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3.1 Objectives of Chapter 
The consensus view that had emerged from receptor homology studies is that 
GluN2B subunit-selective antagonists such as ifenprodil and RO 25-6981 bind to 
the ATD of the GluN2B subunit to elicit receptor inhibition. The binding site, in 
particular, has been mapped to the central cleft of the ATD, as site-directed 
mutagenesis has identified several cleft residues to be critical to receptor 
inhibition. These structural studies had relied on homology modeling as the 
crystal structure of the GluN2B ATD had not been elucidated at that time. 
Recently, the crystal structure of the GluN2B ATD was elucidated and reported 
by Karakas et al. (2009). Hence, in this chapter, we attempted to (i) dock YY1 
into the central cleft of the GluN2B ATD crystal structure, (ii) examine its 
binding conformation with respect to cleft residues previously identified to be 
critical in influencing receptor inhibition, as well as (iii) identify new residues that 
could potentially be important in influencing receptor inhibition (Figure 3-1).  
 
                                    Crystal structure of GluN2B ATD 
                             Dock YY1 into the central cleft of the ATD 
 
 
Examine binding conformation                       Identify new residues that could  
of YY1 with respect to critical                  potentially influence receptor inhibition 
           cleft residues 
 
                                                            Evaluate effect of             Evaluate effect of  
                                                  residue on receptor activation   residue on receptor  
                                                     by glutamate and glycine        inhibition by YY1  
 
 





3.2 Materials and Methods 
 
3.2.1 Materials 
Magnesium sulfate, 3-amino-benzoic acid ethylester, calcium chloride, sodium 
chloride, sodium bicarbonate, potassium chloride, glycine, L-glutamic acid, 
barium chloride, HEPES, dimethyl sulfoxide, penicillin-streptomycin, 
collagenase, from Clostridium histolyticum and ifenprodil were obtained from 
Sigma (St. Louis, MO, USA); Gentamycin was obtained from Gibco (Carlsbad, 
CA, USA).  
 
The crystal structure of the zinc-bound GluN2B ATD (PDB ID. 3JPY) 
was obtained from the Protein Data Bank. 
 
3.2.2 Docking and Molecular Dynamics Simulations 
Docking simulations. The docking simulations of YY1 into the binding site of the 
GluN2B ATD crystal structure were performed by the Glide module in the 
Schrodinger software suite. The shape and properties of the binding site of both 
the closed-cleft and open-cleft ATD (hereafter named C-ATD and O-ATD 
respectively) were represented on a grid, which was generated as pre-processing 
steps for the docking simulations. The CA atom of the residue Methionine 132 
(Met132), which lies in the center of the binding pocket, was adopted as the 




Molecular dynamics and steered molecular dynamics simulations.  Both classical 
and steered molecular dynamics (MD) simulations were carried out using the 
AMBER10 program package with the all-atom force field by Cornell et al. 
(1995). The starting geometry for the simulations was initiated with the X-ray 
structure from the Protein Data Bank (PDB ID. 3JPY).  All simulations were 
performed at neutral pH. Lysine (Lys) and arginine (Arg) residues were positively 
charged while aspartic acid (Asp) and glutamic acid (Glu) residues were 
negatively charged. The default histidine (His) protonation state in Amber10 was 
adopted. Counter ions were added to maintain the eletroneutrality of all the 
systems. The classical and steered MD systems were immersed in 10 Å and 20 Å 
layer truncated octahedron periodic boxes of TIP3P water molecules, 
respectively. The size of the solvent box in the steered MD simulations was 
carefully chosen to ensure that it was large enough to envelope the proteins by 
water molecules at the end of the pulling as well as to keep computational time 
feasible. A 2 fs time step was used in all the simulations. Long-range electrostatic 
interactions were treated with the particle-mesh Ewald (PME) procedure using a 
cubic B-spline interpolation and a 10-5 tolerance for the direct-space with a 12 Å 
non-bonded cutoff. Bond lengths involving hydrogen atoms were constrained 
using the SHAKE algorithm. All systems were minimized prior to the production 
run. The minimization, performed with the SANDER module under constant 
volume condition, consisted of four steps. All heavy atoms in both proteins and 
ligand were restrained with degressive forces of 500, 100, 5 kcal/mol*Å, 
respectively. Firstly, the solvent molecules and hydrogen atoms of the systems 
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were subjected to 250 cycles of steepest descent followed by 250 cycles of 
conjugate gradient minimization. All systems were then relaxed by 500 cycles of 
steepest descent. The systems were subjected to 1000 cycles of conjugate gradient 
minimization in the last step. After the minimization process, the systems were 
heated to 300 K in four steps. Briefly, the systems were first heated to 100 K over 
10 ps, followed by 200 K over the next 10 ps. The systems were then heated to 
250 K for the next 10 ps and subsequently 300 K in the last 20 ps. The production 
parts of the classical MDs of the C(O)-ATD/YY1 were carried out over 5 ns in 
the NPT ensemble at 300 K with Berendsen temperature coupling and constant 
pressure (1 atm) with isotropic molecule-based scaling. A 150 ps equilibrium 
running was followed by the steered MD simulations. A spring constant of 10 
kcal/mol/Å2 was applied to pull the R1 and R2 domains in the ATD. The complex 
was separated at a speed of 4 m/s until the space between the domains was proper 
enough to accommodate the ligand. The selection of the spring constants and the 
pulling speed was also under the consideration of keeping the computational time 
practicable. The mass centers of the pulling force were placed on the average 
positions of all the CA atoms of R1 and R2 domains, respectively. Snapshots of 
the protein were extracted every 10 ps (0.4 Å) during the pulling and when the 
receptor accommodates the ligand. The docking and molecular dynamics 
simulations described above were performed by Dr Zhang Bing previously from 





3.2.3 NMDA Receptor Subunits cDNAs 
Met132 of the GluN2B subunit was mutated to Ser132 using standard molecular 
method. Briefly, site-directed mutagenesis of Met132 was performed by overlap 
PCR using mutagenic primers (5’-CGCCATTATCGAAGATGAG-3’ and 5’-
CTCATCTTCGATAATGGCG-3’) and flanking primers (5’-
ACTTCCATCATCTCTCAG-3’ and 5’-AGAGGGTCCACGCTTTC-3’) to 
generate intermediate PCR products that are overlapping fragments of a portion of 
the GluN2B subunit. Strands of each intermediate product hybridize at their 
overlapping and complementary regions (contained the desired mutation) to form 
the final GluN2B mutated product. The pcDNA1 GluN2B wild-type plasmid was 
digested with Xma I and Kas I, and the GluN2B mutated product was ligated into 
the digested plasmid using T4 ligase. The ligated product was transformed into 
XL-2 Blue ultracompetent E. coli and positive clones were verified by DNA 
sequencing to confirm the successful mutation of Met132. The mutant was named 
GluN2B(M132S). 
 
3.2.4 Expression of GluN1/GluN2B Receptors in Xenopus Oocytes 
Xenopus oocytes and cRNAs were prepared as described in Section 2.26 (p. 46). 
The oocytes were then injected under the magnification of a Nikon SMZ645 
dissecting scope (Nikon, Japan) within 24 hours of isolation with 10-15 ng of 
cRNAs in a 50 nL volume using oocyte microinjection pipettes (Drummond 
Scientific Co., Broomall, PA, USA) mounted on a Marzhauser MM33 
micromanipulator (SDR, Australia) and the ratios of GluN1 to GluN2Bwt and 
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GluN1 to GluN2B(M132S) injected cRNAs were both 3:7. The injected oocytes 
were incubated in Barth’s solution at 17°C for 3-7 days.  
 
3.2.5 Two-Electrode Voltage Clamp Electrophysiology 
Two-electrode voltage clamp recordings on oocytes were performed as described 
in Section 2.2.7 (p. 47). Glutamate (0.03-100 μM) and glycine (0.03-100 μM) 
were used for the agonist dose response oocyte experiments while glutamate (100 
μM), glycine (100 μM) and YY1 (1-10000 nM) were used for YY1 inhibition 
oocyte experiments. Experimental manipulations for agonist dose response were 
expressed as a % of the saturating glutamate and glycine response while 
experimental manipulations for YY1 inhibition was expressed as a % of the pre-
event control response. All data were pooled. YY1 inhibition data were fitted 
(least square criterion) to the equation: 
                 % Response = (100 - minimum)/ (1 + ([antagonist]/IC50)n) + minimum 
where n is the Hill slope, IC50 is the nominal concentration of YY1 that produces 
50% inhibition, and minimum is a residual current response.  
 
3.2.6 Data and Statistical Analyses   
The modeling diagrams were generated using pyMOL. Oocyte recordings were 
analyzed and dose-response curves fitted as described in Section 2.2.8 (p. 48). 
Data were analyzed using unpaired t-test to determine significant differences. 
Values of P<0.05 were considered to be statistically significant. Results are 
presented as mean ± SEM. 
3.3 Results 
 
3.3.1 Docking and molecular dynamics simulations of YY1 
The crystal structure of the GluN2B ATD was revealed to assume an overall 
clamshell-like architecture, composed of two domains (R1 and R2) bound 
together by three well-structured loops (Figure 3-2) (Karakas et al., 2009). The 
crystal structure was very much similar to the structure of the leucine isoleucine 
valine binding protein (LIVBP), which studies have previously relied on to 
construct their GluN2B ATD 3D model. With the present crystal structure of the 
ATD, we attempted to dock YY1 into the cleft between the two domains, where 
other GluN2B subunit-selective antagonists such as ifenprodil have been 
proposed to bind.    
 
 
Figure 3-2 Crystal structure of the GluN2B ATD. The crystal structure of the 
zinc-bound GluN2B ATD (PDB ID. 3JPY) was obtained from the Protein Data 
Bank. The overall structure of the ATD resembles a clamshell, composing of two 





3.3.1.1 YY1 was docked into the open-cleft conformation of the ATD 
Docking simulations were carried out on the zinc-bound state of the 
GluN2B ATD (PDB ID. 3JPY) (Karakas et al., 2009). Initial observations of the 
ATD, however, suggested that the cleft between the R1 and R2 domains may be 
too compact to accommodate YY1. The solvent accessible surface over the ATD 
clearly showed no clear space between the two domains that could accommodate 
any ligand (Figure 3-3A).  Subsequent docking simulations confirmed that the 
cleft was indeed too compact for ligand binding, as YY1 was positioned at the 
edge of the cleft in the docking model.  
 
The GluN2B ATD has been suggested to oscillate between the open-cleft 
and closed-cleft conformations favouring channel opening and closing 
respectively (Gielen et al., 2009; Karakas et al., 2009). Hence, to allow for the 
docking of YY1 in the central cleft, a spring constant of 10 kcal/mol/A2 was 
applied to pull apart the R1 and R2 domains to model an open-cleft conformation 
(hereafter referred to as O-ATD).  The domains were pulled apart at a speed of 4 
m/s, till the space between the domains was large enough to accommodate YY1 













Figure 3-3 The cleft of the GluN2B ATD was too compact to accommodate 
YY1. The zinc bound state of the GluN2B ATD (PDB ID. 3JPY) was used for the 
docking of YY1. (A) The solvent accessible surface of the ATD, however, 
showed no clear space between the R1 and R2 domains for YY1 docking. (B) A 
spring constant was thus applied to pull apart the R1 and R2 domains, so that the 
space at the cleft was proper enough to accommodate YY1. The red arrows 












Figure 3-4 Docking of YY1 into the open-cleft conformation of the GluN2B 
ATD. With the open-cleft conformation, YY1 (in red) was positioned into the 
central cleft in the docking model. The figure was enlarged to allow for a clearer 






3.3.1.2 YY1 adopted a stable conformation in the cleft of the ATD  
The stability of the docked YY1 in the O-ATD was evaluated through 
long-time MD simulations and the root mean square deviation (RMSD) values 
obtained were plotted (Figure 3-5). Docking of YY1 into the O-ATD was shown 
to be stable, as fluctuations of the YY1-(O)ATD curve (Figure 3-5) subsequently 
reach a stable state after 1.5 ns. Initial fluctuations indicated that YY1 underwent 
a conformational and positional adjustment, so as to attain the most appropriate 
docking conformation in the ATD cleft. 
 





















Figure 3-5 Stability of YY1 in the GluN2B ATD cleft. The stability of YY1 and 
the YY1-(O)ATD complex was evaluated by long time MD simulations and their 
RMSD values were plotted. Fluctuations of the YY1-(O)ATD curve was 
observed, which subsequently reached a stable state after 1.5 ns. This indicated 





3.3.1.3 Binding conformation of YY1 with respect to critical cleft 
residues  
Site-directed mutagenesis studies have previously identified several 
residues that play a critical role in controlling the high affinity inhibition by 
GluN2B subunit-selective antagonists such as ifenprodil and RO 25-6981. These 
residues were mapped to regions lining the ATD cleft, and can be grouped based 
on their chemical nature to form distinct clusters in the binding site. We examined 
the binding conformation of YY1 in the ATD cleft, determining if it was 
consistent with these published mutagenesis data.  
 
A close evaluation of the docking model revealed that YY1 adopted a 
binding conformation in good agreement with that previously proposed for 
GluN2B subunit-selective antagonists (Malherbe et al., 2003; Mony et al., 2009; 
Ng et al., 2008; Perin-Dureau et al., 2002). One common structural feature for the 
family of GluN2B antagonists is that the phenyl moiety of the compounds 
interacts with the hydrophobic cluster of residues in the binding cleft (Chenard et 
al., 1999; Tamiz et al., 1998). This structural feature was observed for YY1, as 
shown in Figure 3-6. The phenyl ring of YY1 can be observed to reside in close 
proximity to the hydrophobic cluster of residues, namely Phe176, Phe182, Ile150, 
Tyr231 and Leu261.  
   
Another structural feature for this family of compounds is that a second 
phenyl group coupled with a hydrogen bond donor makes hydrophobic and polar 
interactions with residues in the cleft (Chenard et al., 1999; Tamiz et al., 1998). 
This structural feature was consistent for YY1 as well, as it can be observed that 
the hydroxyl group of YY1 resides near hydrophobic and polar residues such as 
Val42, Asp77 and Thr76 at the entrance of the cleft (Figure 3-7).  
 
 
Figure 3-6 The phenyl moiety of YY1 resides near the hydrophobic cluster of 
residues. The binding conformation of YY1 (in red) is in good agreement with 
that previously proposed for GluN2B subunit-selective antagonists. In particular, 
the phenyl ring (circled in red) of YY1 resides in close proximity to hydrophobic 





Figure 3-7 The hydroxyl group of YY1 resides near the cluster of 
hydrophobic and polar residues. The hydroxyl group (circled in red) of YY1 
could make hydrophobic and polar interactions with residues Val42, Asp 77 and 





3.3.1.4 Effect of Methionine 132 (Met 132) on NMDAR inhibition  
In an attempt to identify new residues that could potentially play an 
important role in influencing receptor inhibition, residue Met132 was identified to 
be a likely candidate. As shown in Figure 3-8, Met132 is located in the R1 
domain of the ATD structure, with its side chain projecting into the binding cleft. 
It was thus suggested to be a potential candidate, as it appears to present a steric 







Figure 3-8 Met132 may influence NMDAR inhibition. Met132 is located in the 
R1 domain of the ATD, and may present a steric hinderance in the binding site 
with its side chain projecting into the central cleft. The figure was enlarged to 





3.3.2 Site-directed mutagenesis of Met132 
The role of Met132 in NMDAR function was assessed by site-directed 
mutagenesis, where the methionine residue was substituted with a serine residue 
(mutant referred to as M132S). Substitution to a serine residue was chosen as the 
chemical nature of serine, being hydrophilic and polar, is vastly different from 
methionine which is hydrophobic and non-polar. Briefly, GluN1 and GluN2Bwt 
or GluN1 and GluN2B(M132S) subunits were expressed in Xenopus oocytes, and 
the effect of M132S on activation and inhibition of NMDAR function was 
assessed.  
  
3.3.2.1 Effect of M132S on glutamate and glycine NMDAR affinities 
The effect of M132S on the dose response activation of GluN1/GluN2B 
receptors by glutamate and glycine was first assessed. Oocytes expressing the 
GluN1/GluN2Bwt and GluN1/GluN2B(M132S) receptors were exposed to 
saturating concentrations of glutamate (100 μM) or glycine (100 μM), and 
NMDA currents induced by increasing concentrations of glycine (0.03-100 μM) 
or glutamate (0.03-100 μM) were recorded respectively.   
 
The glutamate concentration-response curves for both GluN1/GluN2Bwt 
and GluN1/GluN2B(M132S) receptors are shown in Figure 3-9A. In the presence 
of saturating concentration of glycine, NMDA currents were shown to be 
gradually induced by increasing concentrations of glutamate in oocytes 
expressing the GluN1/GluN2Bwt and GluN1/GluN2B(M132S) receptors. 
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Oocytes expressing the GluN1/GluN2Bwt receptors yielded an EC50 value of 1.37 
± 0.15 μM (n=11), which was in good agreement with that obtained by other 
previously published reports (Kiss et al., 2005). M132S did not significantly alter 
the EC50 value of glutamate, with oocytes expressing the GluN1/GluN2B(M132S) 
receptors giving an EC50 value of 1.26 ± 0.04 μM (n=8).   
 
The glycine concentration-response curves for both GluN1/GluN2Bwt and 
GluN1/GluN2B(M132S) receptors, on the other hand, are shown in Figure 3-9B. 
NMDA currents were shown to be similarly induced in oocytes expressing the 
GluN1/GluN2Bwt and GluN1/GluN2B(M132S) receptors by increasing 
concentrations of glycine, in the presence of a saturating glutamate concentration. 
The EC50 value of glycine obtained for GluN1/GluN2Bwt receptors was 0.36 ± 
0.03 μM (n=9), in good agreement with that obtained by other studies (Kiss et al., 
2005). Similar to glutamate, no significant change in EC50 value of glycine was 
obtained with the mutation of the Met132 residue, with oocytes expressing the 




















































Figure 3-9 Effect of M132S on glutamate and glycine NMDAR affinities at 
pH7.3. The dose response curves of glutamate (A) and glycine (B) are depicted 
above. In oocytes expressing the GluN1/GluN2Bwt receptors, the EC50 values of 
glutamate and glycine obtained were 1.37 ± 0.15 μM and 0.36 ± 0.03 μM 
respectively. There was no significant change in the EC50 of glutamate and 
glycine with the mutation of the Met132 residue, with glutamate and glycine 
yielding an EC50 value of 1.26 ± 0.04 μM and 0.34 ± 0.03 μM in 
GluN1/GluN2B(M132S) receptors respectively. Analysis by unpaired t-test. Data 
are presented as mean ± SEM, N=8-11 oocytes from at least two separate frogs. 





3.3.2.2 Effect of M132S on YY1-mediated NMDAR inhibition 
The effect of M132S on the inhibition of GluN1/GluN2B receptors by 
YY1 was next assessed. Briefly, NMDA currents were induced by saturating 
concentrations of glutamate (100 μM) and glycine (100 μM), and the inhibition of 
agonist-induced current by YY1 in GluN1/GluN2Bwt and 
GluN1/GluN2B(M132S) receptors was evaluated. 
 
Figure 3-10 shows the YY1 concentration-inhibition curves for both 
GluN1/GluN2Bwt and GluN1/GluN2B(M132S) receptors. Increasing 
concentrations of YY1 was shown to progressively inhibit the current induced by 
saturating concentrations of glutamate and glycine in oocytes expressing the 
GluN1/GluN2Bwt and GluN1/GluN2B(M132S) receptors. The mutation of 
Met132 did not result in any significant change in the IC50 value of YY1, with 
oocytes expressing the GluN1/GluN2Bwt and GluN1/GluN2B(M132S) receptors 
































Figure 3-10 Effect of M132S on YY1-mediated NMDAR inhibition at pH 7.3. 
YY1 inhibition curves for GluN1/GluN2Bwt and GluN1/GluN2B(M132S) 
receptors are plotted above. There was no change in the IC50 value of YY1 with 
the mutation of Met132, with oocytes expressing the GluN1/GluN2Bwt and 
GluN1/GluN2B(M132S) receptors giving IC50 values of 108 ± 10 nM and 150 ± 
38 nM respectively. Analysis by unpaired t-test. Data are presented as mean ± 
SEM, N=11-12 oocytes from at least two separate frogs. Error bars are shown 










 The GluN2B subunit has received considerable attention in recent years 
due to its role in excitotoxic cell death. Many GluN2B subunit-selective 
antagonists in particular, have shown efficacy in several animal models of 
neurological disorders. Numerous studies have thus attempted to identify the 
structural determinants responsible for their subunit selectively, in the hope that 
the structural knowledge would aid in rational drug design. 
 
The consensus view that had emerged over the years from homology 
studies on NMDARs is that GluN2B subunit-selective antagonists such as 
ifenprodil bind to the GluN2B ATD for receptor inhibition (Malherbe et al., 2003; 
Mony et al., 2009; Ng et al., 2008; Perin-Dureau et al., 2002). Studies 
investigating the structure-activity relationships (SAR) of these antagonists have 
also suggested a common pharmacophore for the putative binding site, the main 
features of which consisted of three major sub-sites (Chenard et al., 1999; Tamiz 
et al., 1998). In particular, the binding site in the ATD was proposed to be made 
up of a hydrophobic sub-site accommodating the phenyl ring, an electrostatic sub-
site interacting with the central basic nitrogen atom and a hydrophobic and 
electrostatic sub-site accommodating the hydrogen bond donor group (Chenard et 
al., 1999; Tamiz et al., 1998).  
 
In view of the pharmacophore model proposed, extensive efforts were 
made in subsequent studies to unravel the molecular determinants important for 
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subunit specific receptor inhibition at the ATD. In particular, Perin-Dureau et al. 
(2002) had performed alanine mutagenesis scans in regions of the ATD to identify 
residues that could be important for the formation of the antagonist binding site. A 
total of 13 residues of diverse chemical nature were identified to exert critical 
influence on ifenprodil inhibition and all were mapped to regions lining the 
central cleft. These residues could also be grouped according to the 
pharmacophore model proposed, consisting of a central polar and negatively 
charged cluster surrounded by two hydrophobic clusters, one comprising of 
hydrophobic residues Phe176, Phe182 and Ile150 and the other comprising of 
residues Val42, Thr76 and Asp77. These observations in all suggest that GluN2B 
subunit-selective antagonists may bind to the cleft of the ATD and could mediate 
receptor inhibition through a mechanism that resembles a Venus-flytrap.  
 
Most of the functional and biochemical studies performed previously had 
relied on homology modeling as the crystal structure of the GluN2B ATD had not 
been elucidated at that time. Recently, the crystal structure of the GluN2B ATD 
was solved and reported by Karakas et al. (2009). Hence, in this chapter, we 
attempted to dock YY1 into the central cleft of the ATD and examine its binding 
conformation with respect to the pharmacophore model previously proposed. 
YY1 was observed to have a SAR that is similar to that of other GluN2B subunit-
selective antagonists. The structure of YY1, in particular, contains a central 
nitrogen atom, with a benzylpiperidine side chain and a hydrogen bond donor 
located at separate ends of the structure. The binding conformation of YY1 was 
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thus expected to confer with the general pharmacophore proposed. Indeed, 
docking simulations of YY1 in the cleft of the ATD crystal structure revealed a 
binding conformation in agreement with the pharmacophore model, where the 
phenyl ring of the benzylpiperidine side chain was observed to be in close 
proximity to the cluster of hydrophobic residues Phe176, Phe182, Ile150 while 
the hydrogen bond donor hydroxyl group was in close proximity to hydrophobic 
and polar residues such as Val42 and Asp77.  
 
Contrary to the conventional view that GluN2B subunit-selective 
antagonists such as ifenprodil and RO 25-6981 bind to the cleft of the ATD for 
receptor inhibition, Karakas et al. (2011) had recently reported that these 
compounds bind to the interface between the GluN1 and GluN2B ATDs instead, 
rather than within the GluN2B ATD cleft itself. In that report, crystallographic 
studies on GluN1b and GluN2B ATD proteins revealed that the ATDs exist as 
heterodimers in both ifenprodil-bound and RO 25-6981-bound forms, and the 
putative binding site was clearly identified at the heterodimer interface (Karakas 
et al., 2011). The contribution of the GluN1 subunit in ifenprodil sensitivity had, 
in fact, been previously reported. Masuko et al. (1999) had previously shown that 
the mutation of several residues in the GluN1 ATD reduced the sensitivity of 
GluN1/GluN2B receptors to ifenprodil. These residues were however suggested 
to be important for the stabilization of the binding site, rather than being in direct 
contact to ifenprodil at that time (Perin-Dureau et al., 2002). The mapping of the 
antagonist binding site to the interface of the GluN1 and GluN2B ATDs could 
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also probably explain the inability of the M132S mutant in affecting YY1 
sensitivity. The Met132 residue was initially suggested to potentially affect ligand 
sensitivity as it was observed to present a steric hindrance in the ATD binding 
cleft. Mutation of the residue, however, was not shown to significantly affect the 
sensitivity of YY1.  
 
In addition to the determination of the antagonist binding site, Karakas and 
colleagues (2011) had also identified several residues at the interface of the 
GluN1 and GluN2B ATDs that had marked effects on the sensitivity of ifenprodil. 
These residues were not among the list of residues previously identified to be 
critical to ifenprodil sensitivity by past site-directed mutagenesis studies. In 
addition, residue Phe176 was the only previously identified residue that was 
demonstrated to affect ifenprodil sensitivity with the newly proposed binding site. 
Certainly, more studies have to be undertaken to fully understand the precise 
mode of binding of the antagonists at their putative binding site. It would not be 
until then that subunit-selective compounds could be designed for therapeutic use 




























4.1 Objective of Chapter  
In addition to determining the NMDAR subunit domain that is important for the 
inhibitory activity of YY1, it would be useful to next investigate the mechanism 
by which YY1 inhibits the GluN1/GluN2B receptors. It has been well established 
that NMDARs are inhibited by protons at physiological pH (Tang et al., 1990; 
Traynelis et al., 1991; Traynelis et al., 1990). GluN2B subunit-selective ATD 
modulators such as ifenprodil and CP-101,606 have also been shown to mediate 
NMDAR inhibition through alterations of this proton inhibition (Mott et al., 
1998). As the inhibition of GluN1/GluN2B receptors by XK1 and XK2 was 
previously demonstrated to be pH-dependent (Wee et al., 2010), we hypothesize 
that YY1 may inhibit NMDAR activity through the alteration of the proton 
inhibition as well. Hence, in this chapter, we attempted to investigate if the 














4.2 Materials and Methods 
 
4.2.1 Materials 
Magnesium sulfate, 3-amino-benzoic acid ethylester, calcium chloride, sodium 
chloride, sodium bicarbonate, potassium chloride, glycine, L-glutamic acid, 
barium chloride, HEPES, dimethyl sulfoxide, penicillin-streptomycin and 
collagenase, from Clostridium histolyticum were obtained from Sigma (St. Louis, 
MO, USA). Gentamycin was obtained from Gibco (Carlsbad, CA, USA).  
 
4.2.2 Expression of GluN1/GluN2B Receptors in Xenopus Oocytes 
Xenopus oocytes and cRNAs were prepared as described in Section 2.26 (p. 46). 
The oocytes were then injected under the magnification of a Nikon SMZ645 
dissecting scope (Nikon, Japan) within 24 hours of isolation with 10-15 ng of 
cRNAs in a 50 nL volume using oocyte microinjection pipettes (Drummond 
Scientific Co., Broomall, PA, USA) mounted on a Marzhauser MM33 
micromanipulator (SDR, Australia) and the ratio of GluN1 to GluN2Bwt injected 
cRNAs was 3:7. The injected oocytes were incubated in Barth’s solution at 17°C 
for 3-7 days.  
 
4.2.3 Two-Electrode Voltage Clamp Electrophysiology 
Two-electrode voltage clamp recordings on oocytes were performed as described 
in Section 2.2.7 (p. 47). Varying concentrations of 0.0003-10 μM of YY1 were 




4.2.4 Data and Statistical Analyses   
Oocyte recordings were analyzed and dose-response curves fitted as described in 
Section 2.2.8 (p. 48). Data was analyzed using one-way analysis of variance 
(ANOVA) followed by post hoc Tukey test. Values of P<0.05 were considered to 


























4.3.1 Inhibition of GluN1/GluN2Bwt receptors by YY1 is pH-sensitive 
To determine if the inhibition of GluN1/GluN2Bwt receptors by YY1 is pH-
sensitive, the degree of inhibition by YY1 was evaluated at pH 6.8, pH 7.3 and 
pH 8.0 in Xenopus oocytes heterologously expressing the GluN1/GluN2Bwt 
receptors. Briefly, GluN1 and GluN2Bwt subunits were expressed in Xenopus 
oocytes, and NMDA currents were induced by saturating concentrations of 
glutamate (100 μM) and glycine (100 μM). The inhibition of agonist-induced 
current by increasing concentrations of YY1 (0.0003-10 μM) was then assessed at 
pH 6.8, pH 7.3 and pH 8.0. 
 
Figure 4-1 shows the concentration-inhibition curves of YY1 plotted from 
oocytes recordings of GluN1/GluN2Bwt receptors measured at pH 6.8, pH 7.3 
and pH 8.0. Inhibition of GluN1/GluN2Bwt receptors by YY1 was shown to be 
pH-dependent, as demonstrated by the shift of the concentration-inhibition curves 
as the pH changes. In particular, a leftward shift observed as the pH level 





























Figure 4-1 Inhibition of GluN1/GluN2Bwt receptors by YY1 is pH-dependent. 
The degree of NMDAR inhibition produced by increasing concentrations of YY1 
was measured at pH 6.8, pH 7.3 and pH 8.0 in Xenopus oocytes heterologously 
expressing the GluN1/GluN2Bwt receptors. The concentration-inhibition curves 
obtained at the three pHs were plotted as shown above. YY1 inhibition of 
GluN1/GluN2Bwt receptors was shown to be pH-dependent, as indicated by the 
shift of the concentration-inhibition curves as the pH changes. The leftward shift, 
in particular, suggested that YY1 functions at a higher potency as the pH level 
decreases. N=10-13 oocytes from at least two separate frogs. Error bars are shown 









The IC50 values obtained from the concentration-inhibition curves were 
plotted in a bar graph as shown in Figure 4-2. The potency of YY1 was shown to 
increase as the pH level decreases, as observed from the significant decrease in 
the IC50 of YY1 when the pH level decreased from pH 8.0 to pH 7.3. In particular, 
the IC50 of YY1 was significantly reduced from 176 ± 7 nM (n=10) at pH 8.0 to a 
value of 108 ± 10 nM (n=11) at pH 7.3 (P<0.001). A further reduction in the IC50 
was also observed when the pH level dropped to pH 6.8, where inhibition by YY1 















Figure 4-2 YY1 inhibition of GluN1/GluN2Bwt receptors was more potent at 
an acidic pH. The IC50 values of YY1 obtained from the concentration-inhibition 
curves were plotted in a bar graph as shown above. A significant reduction in the 
IC50 of YY1 was observed when the pH level decreased from pH 8.0 to pH 7.3 (F 
= 38.90, ***P<0.001). A further reduction in the IC50 was also observed when the 
pH level decreased to pH 6.8 (F = 38.90, **P<0.01), suggesting that the inhibition 
of GluN1/GluN2Bwt receptors by YY1 was more potent at an acidic pH. Analysis 
by one-way ANOVA, followed by post hoc Tukey test. Data are presented as 






 Despite substantial efforts to elucidate the mechanism of ATD-mediated 
inhibition, the mechanism by which GluN2B subunit-selective antagonists inhibit 
NMDAR function still remains unclear. Numerous studies have proposed that 
ifenprodil stabilizes the agonist-bound desensitized state of the receptor which has 
a low open probability (Herin et al., 2004; Reynolds et al., 1989; Yuan et al., 
2009), but the mechanism by which this effect occurs remains unknown.   
 
The proton sensor is a downstream gating element that has been gradually 
gaining attention over the years. NMDARs are widely known to be inhibited by 
protons with an IC50 value that corresponds to pH 7.3 (Tang et al., 1990; 
Traynelis et al., 1991; Traynelis et al., 1990). NMDARs are thus inhibited by 
protons at physiological pH and any change in interstitial pH would certainly 
result in a change in NMDAR function. The pKa of the NMDAR itself could also 
be altered by modulatory substances, influencing the degree by which NMDARs 
are inhibited by protons. Mott and colleagues (1998) had in fact demonstrated that 
ifenprodil and CP-101,606 inhibited NMDARs through the enhancement of the 
proton sensor. Both compounds were shown to shift the pKa of the proton sensor 
to a more alkaline level, making the NMDARs more sensitive to the inhibition by 
protons (Mott et al., 1998). Mott and colleagues (1998) had also suggested that 
the low open probability state of the NMDAR proposed previously corresponds to 




Colquhoun (1998) and Monod et al. (1965) had stated that agents 
allosterically affecting gating elements are by definition most likely to be affected 
by the gating elements as well. Based on this definition, NMDAR modulators that 
alter the proton sensor would thus be expected to be pH-dependent. Indeed, Mott 
and colleagues (1998) had observed that the inhibition of NMDAR currents by 
ifenprodil and CP-101,606 was potentiated as the pH level decreases. Previous 
work by our laboratory had demonstrated that XK1 and XK2 inhibit 
GluN1/GluN2B receptors in a pH-dependent manner (Wee et al., 2010). This thus 
suggests that the class of 5-substituted benzimidazole derivatives may function 
through the proton sensor as well. It seemed that alteration of proton inhibition 
may be a common mechanism among ATD modulators. 
 
The pH dependence of XK1 and XK2 suggests that YY1 may similarly 
inhibit NMDAR activity through the proton sensor. Hence, in this chapter, we 
attempted to investigate if the inhibition of GluN1/GluN2Bwt receptors by YY1 
is pH-dependent. We evaluated the degree of YY1 inhibition at three different pH 
levels (pH 6.8, 7.3 and 8.0) in Xenopus oocytes heterologously expressing the 
GluN1/GluN2Bwt receptors. As predicted, YY1 could indeed function through 
the enhancement of the proton sensor, as shown by its pH-dependent inhibition of 
GluN1/GluN2Bwt receptors. In particular, the degree of inhibition was observed 




An issue not easily addressed in stroke treatment is the time window 
between the stroke onset and the initiation of stroke treatment. Many promising 
neuroprotective agents have narrow therapeutic windows, but delays in travel 
time, patient hospitalization and stroke diagnosis often make it challenging for 
doctors to initiate these treatments within their optimal time period. Stroke onset 
is also often difficult to define, as patients may not be aware of the symptoms 
when they first surfaced. As such, many of these potential neuroprotective agents 
have failed in clinical trials despite showing good efficacy in preclinical studies. 
In view of the inevitable lag times, pretreatment (prophylactic neuroprotection) 
may in this case offer distinct advantages over post-ischemic stroke treatment.  
 
During cerebral ischemia, large changes in interstitial pH would take place, 
during which pH could fall by 0.5 to approximately 1.0 pH unit (Anderson et al., 
2000; Anderson et al., 1983; Meyer et al., 1986). The pH-dependent potency of 
XK1, XK2 and YY1 may thus suggest their possible use for prophylactic 
neuroprotection in groups of individuals at high risks of cerebral ischemia, as 
these compounds would be minimally active at physiological conditions but more 
active at the onset of ischemia. Drugs like XK1, XK2 and YY1, in particular, 
could be considered for short-term prophylactic neuroprotection in patients 
undergoing surgical procedures that have risks of cerebral ischemic events (eg. 
endovascular therapy) or long-term prophylactic neuroprotection in patient 
populations at high risks of stroke (eg. patients with hypertension and 
cerebrovascular atherosclerosis) (Fisher et al., 1994). These compounds would 
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also have an added advantage, through the possibility of selectively inhibiting 
GluN1/GluN2B receptors in ischemic tissues for neuroprotection over unaffected 




























In Vivo Neuroprotective Effects of YY1 and 












5.1 Objective of Chapter  
5-substituted benzimidazole derivatives exemplified by XK1, XK2 and YY1 
showed promise as potential stroke neuroprotectants as they not only exhibited 
potent inhibition of GluN1/GluN2B receptors, but also demonstrated good 
neuroprotective properties in vitro. Their neuroprotective effects in vivo, however, 
have yet to be evaluated. Hence, in this chapter, we attempted to evaluate the 
efficacy of these benzimidazole derivatives as stroke neuroprotectants in vivo. 
Benzylpiperidine benzimidazole YY1 and phenoxyphenyl benzimidazole XK2 
were chosen to be evaluated in a rat model of permanent cerebral ischemia, using 


















5.2 Materials and Methods 
 
5.2.1 Materials 
Dimethyl sulfoxide and 2,3,5-triphenyltetrazolium chloride were obtained from 
Sigma (St. Louis, MO, USA).  
 
5.2.2 Animals and Drugs 
All animal procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) and performed in accordance to the guidelines set by the 
Laboratory Animal Center (LAC), National University of Singapore (NUS) 
adapted from Howard-Jones (1985). Male Wistar rats (250-330g, n=49) were 
obtained from the LAC, NUS and housed in groups of two under diurnal lighting 
conditions with food and water available ad libitum.  
 
YY1 and XK2 were dissolved in 20% dimethyl sulfoxide (DMSO) and 
administered by intraperitoneal (i.p.) injection one hour prior to middle cerebral 
artery occlusion. Vehicle-treated control rats received 20% DMSO only. 
Allocation concealment was achieved by having the drug administration 
performed by another independent researcher.  
 
5.2.3 Permanent Middle Cerebral Artery Occlusion (pMCAO) 
Cerebral ischemia was induced by the permanent unilateral occlusion of the left 
middle cerebral artery (MCA) using a modified sub-temporal approach (Chimon 
et al., 1998; Loo et al., 2002). Rats were anesthetized with ketamine (75 mg/kg) 
102 
 
and xylazine (10 mg/kg) i.p., which was supplementated when necessary during 
the procedure and the total amount used recorded. A skin incision (2 cm) was 
made at the midline of the left ear and the orbit. The underlying skin was 
separated from membranes and retracted to expose the temporal muscle. The 
muscle was removed from the skull surface and retracted to expose the squamosal 
bone. The zygoma was removed with the clearance of the muscle and tissue, and 
the underside of the temporal bone was exposed. A diameter hole (2 mm) was 
created on the squamosal bone by gentle grinding with a dental drill. With the aid 
of a Nikon stereo-zoom microscope, the dura mater was incised and the MCA was 
clearly exposed. The MCA was occluded by electro-cauterization from the origin 
of the lenticulo-striate branches to the junction with the inferior cerebral vein. All 
branches of the MCA within the occluded segment were also cauterized and the 
artery was detached to ensure definitive blood flow interruption. The temporal 
muscle and the skin were closed in layers and sutured.  
 
5.2.4 Neurological Examination 
Neurological examination was evaluated as described by Bederson et al. (1986) 
with modifications. The neurological status of each rat was assessed 24 hours 
after pMCAO. A grading scale of 0 to 4 was used to evaluate the behavioral 
changes of each rat (Table 5-1). The tests described below were conducted 
sequentially; if a rat exhibited the appropriate behaviour at one step but not at the 




Rats were held above the ground by the tail and their forelimb flexion was 
observed. Normal rats extend both forelimbs towards the ground. Rats that extend 
both forelimbs towards the ground were assigned a score of 0. Rats with 
infarction consistently flexed the forelimb contralateral to the side of the 
occlusion and were assigned a score of 1. Rats were then placed on the ground 
and held gently by the tail. Rats that moved spontaneously in all directions but 
showed mono-directional circling towards the paretic side when given a light jerk 
of the tail were assigned a score of 2. Rats were then allowed to move freely and 
observed for circling behaviour. Rats that showed spontaneous contralateral 
circling were assigned a score of 3. Rats that were inactive and moved only when 
stimulated were assigned a score of 4.  
 
Table 5-1 Neurological score for the assessment of ischemic brain injury 
after pMCAO 
Score Neurological Examination 
0 Both forelimbs extended towards the ground 
1 Forelimb contralateral to the side of the occlusion was consistently 
flexed 
2 Moved spontaneously in all directions but showed mono-directional 
circling towards the paretic side when given a light jerk of the tail 
3 Showed spontaneous contralateral circling 
4 Inactive and moved only when stimulated 
 
 
5.2.5 Measurement of Infact Volume 
2,3,5-triphenyltetrazolium chloride (TTC), which gives a faint yellow colour 
when dissolved in phosphate buffered solution, is reduced by dehydrogenase of 
functioning mitochondria to yield a red formazan. As infarct brain tissues lack 
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dehydrogenase, they remained unstained while normal brain tissues are stained 
red, enabling the identification of infarction by gross inspection. Rats were 
sacrificed after neurological examination (24 hours after pMCAO). The rat brains 
were quickly removed after decapitation and all overlying membranes cleared 
using a fine forcep. The cerebra were sectioned into eight coronal slices (2 mm 
thick each) using a rat brain-sectioning block (Kent Scientific, USA) and stained 
with 2% TTC solution for 10 minutes. All slices were arranged in sequence and 
both the anterior and posterior sides were photographed. The infarct volume was 
measured as described below using Image J (National Institutes of Health, 
Bethesda, MD).  
 
The true infarct volume was calculated by correcting for brain edema as 
described by Lin et al. (1993). The area of infarct for each slice was measured 
using the formula RI=LT-RN, where RI = infarct area in the left hemisphere, LT= 
total area in the right hemisphere, and RN= non-infarcted area in the left 
hemisphere. Total infarct volume for each brain was calculated by the summation 
of the infarct area of all brain slices multiplied by the slice thickness (2 mm). The 
average infarct volume was then calculated using the formula (infarct volume of 
the anterior side + infarct volume of the posterior side)/2.  
 
5.2.6 Data and Statistical Analyses   
All data were analyzed and plotted using the GraphPad software. Data for infarct 
volume were analyzed using one-way analysis of variance (ANOVA) followed by 
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post hoc Tukey test to determine significant differences. Data for neurological 
examination were analyzed using chi-square test followed by another post hoc 
chi-square test for multiple group comparison. Values of P<0.05 were considered 



























5.3.1 Neuroprotective effects of YY1 and XK2 in vivo  
The neuroprotective effects of YY1 and XK2 were evaluated in vivo using the rat 
model of permanent cerebral ischemia. Briefly, Wistar rats were randomly 
divided into six experimental groups (Table 5-2): vehicle-treated control group 
for YY1, treatment group for 1 mg/kg YY1, treatment group for 3 mg/kg YY1, 
vehicle-treated control group for XK2, treatment group for 1 mg/kg XK2 and 
treatment group for 3 mg/kg XK2. YY1 and XK2 were administered 
intraperitoneally and cerebral ischemia was induced by the unilateral occlusion of 
the left MCA one hour after drug administration. Drug treatments were 
administered by another researcher to allow for blinding in the study. The 
neuroprotective potentials of the two compounds were then assessed by 
neurological examination and infarct volume measurement 24 hours after 
pMCAO, during which infarction has been reported to be maximal (Kuraoka et al., 








 Table 5-2 Experimental groups of study  
Experimental group Treatment administered (i.p.) 
Vehicle-treated control group for YY1 MCAO + 20% DMSO (vehicle) 
Treatment group for 1 mg/kg YY1 MCAO + 1 mg/kg of YY1 
Treatment group for 3 mg/kg YY1 MCAO + 3 mg/kg of YY1 
Vehicle-treated control group for XK2 MCAO + 20% DMSO (vehicle) 
Treatment group for 1 mg/kg XK2 MCAO + 1 mg/kg of XK2 




                                                                                       Neurological examination 
Drug administration         Induction of                 Infarct volume measurement 
            (i.p.)                    cerebral ischemia                          by TTC staining 
 
          -1 hr                                0 hr                                                   24 hr 
 
 
Figure 5-1 Timeline for the study of the neuroprotective potentials of YY1 













5.3.1.1 YY1 and XK2 reduced infarct volume resulted from pMCAO 
Ischemic brain infarction was evaluated 24 hours after pMCAO. Briefly, 
rats were euthanized and, their cerebra removed and sectioned into eight 2 mm 
thick slices for TTC staining (Figure 5-2). TTC, which gives a faint yellow 
colour when dissolved in phosphate buffered solution, is reduced by 
dehydrogenase of functioning mitochondria to yield a red formazan. As infarct 
brain tissues lack dehydrogenase, they remained unstained while healthy brain 












Figure 5-2 Rat cerebra were sectioned and subjected to TTC staining. Rats 
were euthanized 24 hours after pMCAO and their cerebra removed and sectioned 
into 2 mm thick macrosections. The horizontal and sagittal views of the cerebrum 
are depicted above. The lines indicate the relative positions of transverse cuts 
using a brain sectioning block and the numbers provide labels for the arrangement 
of the sections shown on the right and in Figure 5-3.   
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Representative images of brain slices from the different experimental 
groups after TTC staining are illustrated in Figure 5-3. Figure 5-3A shows a set 
of brain slices from a rat which was sham-operated by omitting the occlusion only. 
No brain infarction was observed, indicating that the surgical procedures did not 
cause brain injury. MCA occlusion, on the other hand, resulted in extensive brain 
infarction in the dorsolateral cortex and the neostriatum (Figure 5-3B). Pre-
ischemic treatment with either YY1 or XK2 was shown to reduce brain infarction 
caused by pMCAO, with increasing neuroprotection observed with an increasing 
dose (Figure 5-3C-F). In particular, reduction in infarction was mainly observed 
in the cortical regions, with minimal protection observed in the striatum (Figure 












(A) Sham-operated            (B) pMCAO only              (C) pMCAO+1mg/kg  
                                                                                              YY1 
                             
 
(D) pMCAO+3mg/kg        (E) pMCAO+1mg/kg        (F) pMCAO+3mg/kg  
      YY1                                    XK2                                    XK2 
     
        
 
Figure 5-3 Neuroprotective effects of YY1 and XK2 in reducing ischemic 
brain infarction. Cerebral ischemia was induced by the permanent unilateral 
occlusion of the left MCA by electrocauterization. YY1 and XK2 were 
administered i.p. one hour prior to the occlusion. Representative images of brain 
slices from the different experimental groups after TTC staining are shown above. 
(A) No brain infarction was observed for the sham-operated rat, indicating that 
surgery did not cause brain injury. (B) MCA occlusion, on the other hand, 
resulted in extensive brain infarction in the dorsolateral cortex and the 
neostriatum. (C-F) Treatment with either YY1 or XK2 reduced brain infarction 






The degree of brain infarction was quantified in terms of infarct volume. 
YY1 and XK2 were shown to reduce infarct volume in a dose-dependent manner, 
with both compounds giving a significant reduction at a dosage of 3 mg/kg 
(Figure 5-4 and 5-5, respectively). As shown in Figure 5-4, vehicle-treated rats 
for YY1 (20% DMSO only) had an infarct volume of 422 ± 31 mm3 (n=8). Rats 
pre-treated with 3 mg/kg of YY1 showed a significant reduction in infarct volume 




Figure 5-4 Pre-ischemic treatment with YY1 reduced infarct volume dose-
dependently. Vehicle-treated rats recorded an infarct volume of 422 ± 31 mm3. 
Pre-treatment with 3 mg/kg of YY1 significantly reduced infarct volume, with 
treated rats recording an infarct volume of 252 ± 49 mm3 [F = 7.50, **P<0.01, 
compared with vehicle-treated group, N=6-8]. The brain sections above each bar 
graph were extracted from the respective treatment groups to illustrate the 
reduction in brain infarction. Analysis by one-way ANOVA, followed by post hoc 
Tukey test. Data are presented as mean infarct volume ± SEM. (n): sample size 
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Vehicle-treated rats for XK2, on the other hand, recorded an infarct 
volume of 373 ± 43 mm3 (n=11). Similar to YY1, pre-treatment with 3 mg/kg of 
XK2 resulted in a 40% reduction in infarct volume, with treated rats recording an 
infarct volume of 223 ± 15 mm3 (n=8, P<0.05). 
 
 
Figure 5-5 Pre-ischemic treatment with XK2 reduced infarct volume dose-
dependently. Vehicle-treated rats recorded an infarct volume of 373 ± 43 mm3. 
Rats pre-treated with 3 mg/kg of XK2 showed a significant reduction in infarct 
volume, giving an infarct volume of 223 ± 15 mm3 [F = 3.73, *P<0.05, compared 
with vehicle-treated group, N=8-11]. Similar to Figure 5-4, the brain sections 
above each bar graph were extracted from the respective treatment groups to 
illustrate the reduction in brain infarction. Analysis by one-way ANOVA, 
followed by post hoc Tukey test. Data are presented as mean infarct volume ± 







5.3.1.2 YY1 and XK2 improved neurological behaviour 
Neurological deficits has been shown to correlate with the size of brain 
infarction after cerebral ischemia (Bederson et al., 1986). As such, evaluation of 
neurological behavior has also been used as a method of assessing post-ischemic 
brain injury. A grading scale of 0 to 4 is usually used to evaluate the behavioral 
changes of each rat. In particular, the higher the neurological deficit score given, 
the greater is the severity of the brain infarction. In this study, neurological 
deficits were evaluated before euthanasia, 24 hours after pMCAO. As shown in 
Tables 5-3 and 5-4, vehicle-treated rats recorded a median neurological score of 
2.5-3. Neurological behaviour was improved with the pre-ischemic administration 
of XK2, with rats treated with either 1 mg/kg or 3 mg/kg of XK2 recording a 
median score of 2 (P<0.05). Neurological behavior of YY1-treated rats was 










Table 5-3 Effects of YY1 on neurological scores in rats 24 hours after pMCAO 
Neurological score No. of vehicle-treated rats  No. of 1 mg/kg YY1- treated 
rats   
No. of 3 mg/kg YY1- treated 
rats   
1 2 1 1 
2 2 3 3 
3 4 3 2 
4 0 0 0 
Median 2.5 2 2 
95% CI 1.51,2.99 1.59,2.99 1.38,2.96 
Data was analyzed using the chi-square method. χ2 = 1.10, d.f. = 4; P>0.05 
 
 
Table 5-4 Effects of XK2 on neurological scores in rats 24 hours after pMCAO 
Neurological score No. of vehicle-treated rats  No. of 1mg/kg XK2-treated 
rats 
No. of 3mg/kg XK2-treated 
rats 
1 0 2 3 
2 3 6 4 
3 7 1 1 
4 1 0 0 
Median 3 2* 2* 
95% CI 2.41,3.22 1.43,2.35 1.16,2.34 




In this chapter, we evaluated benzylpiperidine benzimidazole YY1 and 
phenoxyphenyl benzimidazole XK2 for any neuroprotective properties in vivo. 
Their potential as stroke neuroprotectants were suggested as both compounds 
showed high affinity antagonism of the GluN1/GluN2B receptors and good 
efficacy in an in vitro excitotoxicity model. Indeed, administration of YY1 and 
XK2 one hour prior to MCA occlusion was demonstrated to be neuroprotective in 
a rat model of permanent cerebral ischemia. Both compounds reduced ischemic 
infarct volume in a dose-dependent manner, yielding a significant reduction 
comparable to that of other GluN2B subunit-selective antagonists at a dosage of 3 
mg/kg (Gill et al., 2002; Tsuchida et al., 1997). Like most other neuroprotective 
agents, reduction in brain infarction by YY1 and XK2 was mainly observed in the 
cortical area, with minimal protection seen in the striatum. This was expected as 
the lenticulostriate branches, which are the main sources of blood supply to the 
striatum, were permanently occluded in the stroke model (Gill et al., 1991).  
 
Ketamine has been reported to have an antagonistic action on the 
NMDAR (Murray et al., 2000), and thus may possibly influence infarct volume. 
No statistically significant correlation, however, was observed when the infarct 
volume was analyzed against the total amount of anaesthetics used for the 
vehicle-treated animals (n=19, P=0.5497. Pearson’s correlation test; data not 
shown), indicating that the anaesthetics did not influence the ischemic outcome in 
these animals after pMCAO. In addition, no correlation could be established 
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between the amount of anaesthetics used and the infarct volume in the YY1/XK2-
treated animals (YY1: P=0.8864; XK2: P=0.0647. Pearson’s correlation test; data 
not shown), suggesting that the ketamine used did not contribute significantly to 
the neuroprotective effects observed for these agents.  
 
Ischemic brain damage post-MCAO can be characterized into two distinct 
phases: immediate neuronal necrosis at the core of the stroke insult and delayed 
cell death in the penumbra region. As the penumbra region is an area of brain 
tissue that is damaged but not yet dead, a window of opportunity exists for 
therapeutic salvage. However, given time and without treatment, excitotoxic 
mechanisms resulting from the uncontrolled overactivation of NMDARs could 
initiate molecular events leading to neuronal apoptosis in the penumbra region. 
Neurons eventually die and the area of infarct widens. We thus hypothesized that 
the neuroprotective potentials of YY1 and XK2 were attributed to the inhibition 
of NMDAR activity during this acute injury phase, thereby containing the extent 
of the stroke insult. Neuronal repair mechanisms would then come into play, as 
the penumbra transitions from the acute injury phase to the recovery phase. 
Certainly, more studies have to be undertaken to validate this hypothesis, where 
studies not only have to investigate the pharmacokinetic profile of the two 
compounds, but also the mechanism and period during which the damaged brain 




One of the reasons for the failure of neuroprotective agents in the clinical 
setting is the discrepancy in the time windows of drug administration between 
animal studies and clinical trials. In the hospital settings, stroke treatment is 
usually administered to patients more than six hours after their stroke onset due to 
time lags in hospitalization and stroke diagnosis. As such, it would be more 
appropriate for preclinical testing of neuroprotective agents to have long windows 
of drug administration (eg. drug administered at least six hours after MCAO) as 
they are more relevant to the clinical situation. A pre-ischemic administration of 
YY1 and XK2 was however chosen for our study as we would like to evaluate 
their potential in prophylactic neuroprotection. The possible use of YY1 and XK2 
in prophylactic neuroprotection was previously suggested when the inhibition of 
GluN1/GluN2B receptors by YY1 and XK2 was shown to be pH-dependent (Wee 
et al., 2010).     
 
The demonstration of neuroprotective efficacy with the pre-ischemic 
administration of YY1 and XK2 may indeed suggest that both compounds could 
be possible prophylactic stroke neuroprotectants. Nevertheless, more studies have 
to be performed, as safety and tolerability aspects of the compounds are important 





























One of the main therapeutic approaches to acute ischemic stroke involves 
neuroprotection, where neuroprotective drugs aim to reduce cell death in the 
ischemic penumbra region. As brain tissues in the penumbra region mainly die 
from apoptosis owing to uncontrolled excitotoxicity mediated by NMDARs, 
many neuroprotection strategies have focused on the down-regulation of NMDAR 
overactivation. Despite the initial optimism, early non-selective NMDAR 
antagonists have repeatedly failed in clinical trials due to inefficacy and adverse 
effects. As such, subunit-selective NMDAR antagonists have been proposed to be 
a safer alternative, with studies focusing on the GluN2B subunit due to its role in 
excitotoxic cell death.  
 
Two classes of 5-substituted benzimidazole derivatives, the 
benzylpiperidine benzimidazoles and the phenoxyphenyl benzimidazoles, have 
been previously reported to be high affinity GluN2B subunit-selective antagonists 
by McCauley and colleagues (2004). Previous work by our laboratory to 
characterize the inhibitory profile of benzylpiperidine benzimidazole XK1 and 
phenoxyphenyl benzimidazole XK2 had also demonstrated that both compounds 
showed good efficacy in an in vitro neuronal excitotoxicty model (Wee et al., 
2010). The demonstration of neuroprotective properties in vitro by these two 
compounds suggested a possible role of 5-substituted benzimidazole derivatives 
as stroke neuroprotectants. Nevertheless, we are unaware of any studies that have 
evaluated their effects in stroke.  Hence in this study, we attempted to expand our 
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work on the class of 5-substituted benzimidazole derivatives, by characterizing 
the inhibitory profile of another benzylpiperidine benzimidazole YY1 and 
evaluating the efficacy of YY1 and XK2 as stroke neuroprotectants in vivo. 
 
The first objective of this study was to evaluate the neuroprotective 
properties of benzylpiperidine benzimidazole YY1 in vitro, as well as characterize 
its inhibition of GluN1/GluN2B receptors. Similar to XK1 and XK2, YY1 was 
demonstrated to be neuroprotective in an in vitro neuronal excitotoxicity model, 
reducing NMDA-induced neuronal death with an IC50 value in the low nanomolar 
range. The GluN2B subunit was also shown to confer sensitivity to YY1, with 
docking studies of YY1 into the crystal structure of the GluN2B ATD revealing a 
binding conformation in agreement with previously published results. YY1 was 
also suggested to inhibit GluN1/GluN2B receptors through the alteration of the 
proton sensor, as demonstrated by its pH-dependent inhibitory effect.  
 
The second objective of this study was to evaluate the efficacy of 5-
substituted benzimidazole derivatives as stroke neuroprotectants in vivo. The in 
vivo neuroprotective properties of a benzylpiperidine benzimidazole (YY1) and a 
phenoxyphenyl benzimidazole (XK2) were evaluated in a rat model of permanent 
cerebral ischemia. Both YY1 and XK2 were shown to be neuroprotective when 
administered one hour prior to MCA occlusion. Both compounds reduced infarct 
volume dose-dependently, with a significant reduction observed at a dosage of 3 
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mg/kg. Neurological deficits were also generally improved in the drug-treated 
groups.    
 
One of the main reasons for the failure of neuroprotective compounds in 
clinical trials is the occurrence of adverse effects. The adverse effect profile of a 
promising candidate would thus be another important factor of consideration in 
addition to its neuroprotective efficacy. Early GluN2B subunit-selective 
antagonists such as ifenprodil and eliprodil, though selective to the GluN2B 
subtype, were plagued with cardiovascular complications as they were also 
antagonists of the α1-adrenergic receptors and hERG channels (Gogas, 2006; 
Wang et al., 2005). YY1 and XK2 may have an improved adverse effect profile 
as compared to these early GluN2B antagonists, as they were previously reported 
to display reduced α1-adrenergic binding (800-5000 fold) and hERG channel 
activity (150-3000 fold) by McCauley et al. (2004). In addition, their pH-
dependent inhibition of GluN1/GluN2B receptors could also suggest the 
possibility of selectively inhibiting GluN1/GluN2B receptors for neuroprotection 
in ischemic tissues while normal NMDA activity is retained in unaffected regions.  
 
In summary, the present results of the study supported the hypothesis that 
5-substituted benzimidazole derivatives are effective neuroprotectants in vivo. 
These benzimidazole derivatives may represent a novel class of neuroprotectants 
with an improved adverse effect profile. In particular, these benzimidazole 
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derivatives could be potentially used in the field of prophylactic neuroprotection, 
given that their inhibitory potency increases as the pH becomes more acidic.  
 
6.2 Limitations of Study 
 The study of human stroke is particularly difficult, owing to the 
tremendous heterogeneity of the disease in terms of stroke subtypes, recovery 
patterns, and associated clinical factors (Gladstone et al., 2002). Animal models 
of stroke could not adequately mimic the clinical situation of cerebral ischemia as 
there are inherent morphological and functional differences between the brains of 
humans and animals (Dirnagl et al., 1999). For example, cerebral energy 
metabolism and blood flow have been showed to be three times higher in rodents 
as compared to humans. The quantitative makeup of neuronal and gial densities in 
the brain are also different in various species of animals. As such, the interspecies 
variability between animals and humans has been proposed to be one of the 
reasons for the repeated failure of many promising neuroprotective candidates in 
acute stroke trials. Although the variability between animals and humans could 
not be completely addressed, the problem could certainly be ameliorated by more 
in-depth studies on the intricate pathophysiology of stroke and appropriate study 
guidelines to allow for robust and detailed preclinical evaluation of 
neuroprotective drugs. Indeed, efforts have already been put in to further 
characterize the physiologic profile of the penumbra, where studies are attempting 
to investigate the transition of the damaged brain from injury to repair after stroke 
(Lo, 2008). In addition, recommendations for preclinical drug development have 
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also been provided to guide researchers in their evaluation of neuroprotective 
compounds (STAIR, 1999).     
   
6.3 Future Directions 
 The demonstration of neuroprotective efficacy of 5-substituted 
benzimidazole derivatives exemplified by XK2 and YY1 when administered one 
hour prior to pMCAO forms the initial step in the evaluation of the suitability of 
this class of compounds as stroke neuroprotectants. Certainly, more in depth 
studies have to be performed to fully characterize the efficacy and safety profiles 
of these benizimidazoles. For example, neuroprotective efficacy of these 
benzimidazoles should also be evaluated in different animal species, as well as in 
multiple models of focal cerebral ischemia such as transient ischemic models. In 
addition, post-ischemic treatment studies, pharmacokinetic studies, toxicity 
studies and chronic treatment studies are important studies that should be in the 
lineup for future work as well. 
 
 In addition to the class of 5-substituted benzimidazole derivatives, 
combinatorial synthesis strategies could be used to design different classes but 
structurally similar compounds. Screening studies could be performed on these 
compounds, so as to identify possible candidates to be evaluated for their use as 
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